Supplementary references (for...

Hirschhorn et al., Comprehensive review of association studies

References1. Lander ES, Schork NJ. Genetic dissection of complex traits (published erratum appears in Science

1994;266(5184):353). Science 1994;265:2037-2048.2. Chakravarti A. Population genetics---making sense out of sequence. Nat Genet 1999;21:56-60.3. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-856.4. Harris H. The principles of human biochemical genetics. Amsterdam: North-Holland Publishing

Company, 1975.5. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin

JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Atshuler D. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-933.

6. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-1008.

7. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.

8. Aparicio C, Dahlback B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996;313:467-472.

9. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn U. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511-518.

10. Dilley A, Austin H, Hooper WC, El-Jamil M, Whitsett C, Wenger NK, Benson J, Evatt B. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998;132:452-455.

11. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-545.

12. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.

13. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A, Graham IM, Whitehead AS. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996;94:2154-2158.

14. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, den Heijer M, Trijbels FJ, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.

1


15. Bailey LB, Gregory JF, 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999;129:919-922.

16. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1071.

17. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC, Scott JM. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM 1995;88:763-766.

18. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-1102.

19. Margaglione M, D'Andrea G, d'Addedda M, Giuliani N, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Brancaccio V, Di Minno G. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998;79:907-911.

20. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999;96:12810-12815.

21. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996;94:2410-2416.

22. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-258.

23. Morrison K, Papapetrou C, Hol FA, Mariman EC, Lynch SA, Burn J, Edwards YH. Susceptibility to spina bifida; an association study of five candidate genes. Ann Hum Genet 1998;62:379-396.

24. Osuntokun BO, Sahota A, Ogunniyi AO, Gureje O, Baiyewu O, Adeyinka A, Oluwole SO, Komolafe O, Hall KS, Unverzagt FW, et al. Lack of an association between apolipoprotein E epsilon 4 and Alzheimer's disease in elderly Nigerians. Ann Neurol 1995;38:463-465.

25. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.

26. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, Mayeux R. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-755.

27. Altshuler D, Kruglyak L, Lander E. Genetic polymorphisms and disease [letter; comment]. N Engl J Med 1998;338:1626.

28. Freely associating. Nat Genet 1999;22:1-2.29. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR,

Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [In Process Citation]. Nat Genet 2000;26:76-80.

2


30. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:91-99.

31. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506-516.

32. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-228.

33. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997-1004.34. Reich DE, Goldstein DB. Detecting association in a case-control study while correcting for

population stratification. Genet Epidemiol 2001;20:4-16.35. Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured

populations. Am J Hum Genet 2000;67:170-181.36. Morton NE, Collins A. Tests and estimates of allelic association in complex inheritance. Proc

Natl Acad Sci U S A 1998;95:11389-11393.37. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W,

Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.

38. Mancini FP, Vaccaro O, Sabatino L, Tufano A, Rivellese AA, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor---gamma2 is not associated with type 2 diabetes. Diabetes 1999;48:1466-1468.

39. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-453.

40. Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P, Vaisse C. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000;24:391-393.

41. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-216.

42. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24:195-199.

43. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 2001;50:886-890.

44. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-894.

45. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999;93:1496-1501.

3


46. Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 1999;20:1225-1229.

47. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2000;9:557-562.

48. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K, Kawamoto T. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999;83:606-609.

49. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-644.

50. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM, Au WW. GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 1998;22:129-138.

51. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-4875.

52. Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in. Int J Cancer 1999;84:350-353.

53. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-463.

54. Taioli E, Trachman J, Chen X, Toniolo P, Garte SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res 1995;55:3757-3758.

55. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33.

56. Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, Shu XO, Gao YT. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:147-150.

57. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000;92:412-417.

58. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum Genet 1994;94:665-670.

59. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Watson M, Comstock GW, Bell D. Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 1998;90:512-518.

60. Lidereau R, Escot C, Theillet C, Champeme MH, Brunet M, Gest J, Callahan R. High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst 1986;77:697-701.

61. Chouchane L, Ahmed SB, Baccouche S, Remadi S. Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 1997;80:1489-1496.

4


62. Zheng W, Deitz AC, Campbell DR, Wen WQ, Cerhan JR, Sellers TA, Folsom AR, Hein DW. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:233-239.

63. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995;4:231-236.

64. Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 2000;60:2348-2350.

65. Becchis M, Frairia R, Ferrera P, Fazzari A, Ondei S, Alfarano A, Coluccia C, Biglia N, Sismondi P, Fortunati N. The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. Breast Cancer Res Treat 1999;54:101-107.

66. Ambrosone CB, Coles BF, Freudenheim JL, Shields PG. Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. J Nutr 1999;129:565S-568S.

67. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-1316.

68. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999;83:723-726.

69. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer 2000;88:2082-2091.

70. Piyathilake CJ, Macaluso M, Johanning GL, Whiteside M, Heimburger DC, Giuliano A. Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia. Anticancer Res 2000;20:1751-1757.

71. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-234.

72. Crossen PE, Morrison MJ. Elevated frequency of an ETS-1 restriction fragment polymorphism in chronic B-cell leukaemia. Hum Genet 1993;91:380-382.

73. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol 1997;97:107-112.

74. Yokoyama A, Muramatsu T, Ohmori T, Yokoyama T, Okuyama K, Takahashi H, Hasegawa Y, Higuchi S, Maruyama K, Shirakura K, Ishii H. Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 1998;19:1383-1387.

75. Gryfe R, Di Nicola N, Lal G, Gallinger S, Redston M. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 1999;64:378-384.

76. Sivaraman L, Leatham MP, Yee J, Wilkens LR, Lau AF, Le Marchand L. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res 1994;54:3692-3695.

77. Lafuente MJ, Casterad X, Trias M, Ascaso C, Molina R, Ballesta A, Zheng S, Wiencke JK, Lafuente A. NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-1819.

5


78. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993;14:1821-1824.

79. Deakin M, Elder J, Hendrickse C, Peckham D, Baldwin D, Pantin C, Wild N, Leopard P, Bell DA, Jones P, Duncan H, Brannigan K, Alldersea J, Fryer AA, Strange RC. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17:881-884.

80. Park KS, Mok JW, Rho SA, Kim JC. Analysis of TNFB and TNFA NcoI RFLP in colorectal cancer. Mol Cells 1998;8:246-249.

81. Orimo H, Nakajima E, Yamamoto M, Ikejima M, Emi M, Shimada T. Association between single nucleotide polymorphisms in the hMSH3 gene and sporadic colon cancer with microsatellite instability. J Hum Genet 2000;45:228-230.

82. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995;55:3537-3542.

83. Gil JP, Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998;19:37-41.

84. Abdel-Rahman SZ, Soliman AS, Bondy ML, Omar S, El-Badawy SA, Khaled HM, Seifeldin IA, Levin B. Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt. Cancer Lett 2000;159:79-86.

85. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K, Wake N. WAF1 genotype and endometrial cancer susceptibility. Gynecol Oncol 1999;72:187-192.

86. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 1997;18:2307-2311.

87. Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y, Minaguchi T, Nakamura Y, Tokino T, Kudo R. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 2000;91:612-615.

88. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997;75:1385-1388.

89. Katoh T, Nagata N, Kuroda Y, Itoh H, Kawahara A, Kuroki N, Ookuma R, Bell DA. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis 1996;17:1855-1859.

90. Setiawan VW, Zhang ZF, Yu GP, Li YL, Lu ML, Tsai CJ, Cordova D, Wang MR, Guo CH, Yu SZ, Kurtz RC. GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev 2000;9:73-80.

91. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Jr., Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.

92. Shibuta K, Mori M, Haraguchi M, Yoshikawa K, Ueo H, Akiyoshi T. Association between restriction fragment length polymorphism of the L-myc gene and susceptibility to gastric cancer. Br J Surg 1998;85:681-684.

6


93. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, Prior TW, Plass C, von Deimling A, Black PM, Yates AJ, Eng C. Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet 2000;37:410-414.

94. Hori H, Kawano T, Endo M, Yuasa Y. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J Clin Gastroenterol 1997;25:568-575.

95. Ralhan R, Agarwal S, Mathur M, Wasylyk B, Srivastava A. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. Clin Cancer Res 2000;6:2440-2447.

96. Park JY, Muscat JE, Ren Q, Schantz SP, Harwick RD, Stern JC, Pike V, Richie JP, Jr., Lazarus P. CYP1A1 and GSTM1 polymorphisms and oral cancer risk [published erratum appears in Cancer Epidemiol Biomarkers Prev 1997 Dec;6(12):1108]. Cancer Epidemiol Biomarkers Prev 1997;6:791-797.

97. Worrall SF, Corrigan M, High A, Starr D, Matthias C, Wolf CR, Jones PW, Hand P, Gilford J, Farrell WE, Hoban P, Fryer AA, Strange RC. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998;8:433-439.

98. Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF. Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiol Biomarkers Prev 1998;7:1013-1018.

99. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000;9:843-847.

100. Trizna Z, Clayman GL, Spitz MR, Briggs KL, Goepfert H. Glutathione s-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.

101. Jahnke V, Strange R, Matthias C, Fryer A. Glutathione S-transferase and cytochrome P450 genotypes as risk factors for laryngeal carcinoma. Eur Arch Otorhinolaryngol Suppl 1997;1:S147-149.

102. Morita S, Yano M, Tsujinaka T, Ogawa A, Taniguchi M, Kaneko K, Shiozaki H, Doki Y, Inoue M, Monden M. Association between genetic polymorphisms of glutathione S-transferase P1 and N-acetyltransferase 2 and susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 1998;79:517-520.

103. Matthias C, Jahnke V, Fryer A, Strange R, Ollier W, Hajeer A. Influence of tumour necrosis factor microsatellite polymorphisms on susceptibility to head and neck cancer. Acta Otolaryngol 1998;118:284-288.

104. Shibuta K, Inoue H, Sato K, Matsuyama A, Ueo H, Tanaka Y, Mafune K, Barnard GF, Mori M. L-myc restriction fragment length polymorphism in Japanese patients with esophageal cancer. Jpn J Cancer Res 2000;91:199-203.

105. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S- transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294-298.

106. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L, Beckman G. p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered 1996;46:49-54.

107. Agundez JA, Ledesma MC, Benitez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, Diaz-Rubio M. CYP2D6 genes and risk of liver cancer. Lancet 1995;345:830-831.

7


108. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-1273.

109. Wong NA, Rae F, Bathgate A, Smith CA, Harrison DJ. Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. Toxicol Lett 2000;115:17-22.

110. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered 1996;46:221-225.

111. Hamada GS, Sugimura H, Suzuki I, Nagura K, Kiyokawa E, Iwase T, Tanaka M, Takahashi T, Watanabe S, Kino I, et al. The heme-binding region polymorphism of cytochrome P450IA1 (CypIA1), rather than the RsaI polymorphism of IIE1 (CypIIE1), is associated with lung cancer in Rio de Janeiro. Cancer Epidemiol Biomarkers Prev 1995;4:63-67.

112. Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato K, Ariyoshi N, Kamataki T. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 1999;261:658-660.

113. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 1991;82:254-256.

114. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6:87-92.

115. Wiencke JK, Spitz MR, McMillan A, Kelsey KT. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev 1997;6:87-92.

116. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998;58:5291-5293.

117. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, Albanes D. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 2000;60:6381-6383.

118. Sun GF, Shimojo N, Pi JB, Lee S, Kumagai Y. Gene deficiency of glutathione S-transferase mu isoform associated with susceptibility to lung cancer in a Chinese population. Cancer Lett 1997;113:169-172.

119. Kelsey KT, Spitz MR, Zuo ZF, Wiencke JK. Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). Cancer Causes Control 1997;8:554-559.

120. Lindstedt BA, Ryberg D, Zienolddiny S, Khan H, Haugen A. Hras1 VNTR alleles as susceptibility markers for lung cancer: relationship to microsatellite instability in tumors. Anticancer Res 1999;19:5523-5527.

121. Shimura T, Hagihara M, Takebe K, Munkhbat B, Odaka T, Kato H, Nagamachi Y, Tsuji K. The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer 1994;73:1184-1188.

122. Ishida T, Takashima R, Fukayama M, Hamada C, Hippo Y, Fujii T, Moriyama S, Matsuba C, Nakahori Y, Morita H, Yazaki Y, Kodama T, Nishimura S, Aburatani H. New DNA polymorphisms of human MMH/OGG1 gene: prevalence of one polymorphism among lung-adenocarcinoma patients in Japanese. Int J Cancer 1999;80:18-21.

8


123. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-5003.

124. Abdel-Rahman SZ, El-Zein RA, Zwischenberger JB, Au WW. Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers. Mutat Res 1998;398:43-54.

125. Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-298.

126. Hirvonen A, Saarikoski ST, Linnainmaa K, Koskinen K, Husgafvel-Pursiainen K, Mattson K, Vainio H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 1996;88:1853-1856.

127. Sikstrom C, Beckman LE, Eklund A, Beckman L. Transferrin C3 offers protection against smoking-associated lung cancer? Carcinogenesis 1996;17:1447-1449.

128. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 1993;14:1085-1089.

129. Radice P, Pierotti MA, Borrello MG, Illeni MT, Rovini D, Della Porta G. HRAS1 proto-oncogene polymorphisms in human malignant melanoma: TaqI defined alleles significantly associated with the disease. Oncogene 1987;2:91-95.

130. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, Jackson IJ, Rees JL. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663-1666.

131. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000;60:5612-5616.

132. Crossen PE, Morrison MJ, Colls BM. Elevated frequency of a SstI polymorphism of the Ets-1 oncogene in non-Hodgkin's lymphoma patients. Cancer Genet Cytogenet 1995;79:70-73.

133. Nair UJ, Nair J, Mathew B, Bartsch H. Glutathione S-transferase M1 and T1 null genotypes as risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers. Carcinogenesis 1999;20:743-748.

134. Bartsch H, Rojas M, Nair U, Nair J, Alexandrov K. Genetic cancer susceptibility and DNA adducts: studies in smokers, tobacco chewers, and coke oven workers. Cancer Detect Prev 1999;23:445-453.

135. Weitzel JN, Ding S, Larson GP, Nelson RA, Goodman A, Grendys EC, Ball HG, Krontiris TG. The HRAS1 minisatellite locus and risk of ovarian cancer. Cancer Res 2000;60:259-261.

136. Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer 1999;81:179-183.

137. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer [published erratum appears in Proc Natl Acad Sci U S A 1997 Jul 22;94(15):8272]. Proc Natl Acad Sci U S A 1997;94:3320-3323.

138. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997;89:166-170.

9


139. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9:635-639.

140. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-1731.

141. Murata M, Shiraishi T, Fukutome K, Watanabe M, Nagao M, Kubota Y, Ito H, Kawamura J, Yatani R. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol 1998;28:657-660.

142. Tang YM, Green BL, Chen GF, Thompson PA, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-766.

143. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999;8:901-905.

144. Rebbeck TR, Walker AH, Zeigler-Johnson C, Weisburg S, Martin AM, Nathanson KL, Wein AJ, Malkowicz SB. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000;67:1014-1019.

145. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975-978.

146. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-4110.

147. Longuemaux S, Delomenie C, Gallou C, Mejean A, Vincent-Viry M, Bouvier R, Droz D, Krishnamoorthy R, Galteau MM, Junien C, Beroud C, Dupret JM. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res 1999;59:2903-2908.

148. Sweeney C, Farrow DC, Schwartz SM, Eaton DL, Checkoway H, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:449-454.

149. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-644.

150. Higashi K, Ishikawa T, Ito T, Yonemura A, Shige H, Nakamura H. Association of a genetic variation in the beta 3-adrenergic receptor gene with coronary heart disease among Japanese. Biochem Biophys Res Commun 1997;232:728-730.

151. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetiere P, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-913.

152. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueck CJ, Vergani C, Wilson PW, Karathanasis SK. Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med 1986;314:671-677.

153. Hegele RA, Huang LS, Herbert PN, Blum CB, Buring JE, Hennekens CH, Breslow JL. Apolipoprotein B-gene DNA polymorphisms associated with myocardial infarction. N Engl J Med 1986;315:1509-1515.

10


154. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879-880.

155. Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, Schmitz G. C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999;99:3218-3220.

156. Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H, Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998;97:135-137.

157. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998;79:8-13.

158. Arruda VR, Siquiera LH, Chiaparini LC, Coelho OR, Mansur AP, Ramires A, Annichino-Bizzacchi JM. Prevalence of the prothrombin gene variant 20210 G --> A among patients with myocardial infarction. Cardiovasc Res 1998;37:42-45.

159. Le W, Yu JD, Lu L, Tao R, You B, Cai X, Cao WJ, Huang W, He RM, Zhu DL, Chen Z, Gong LS. Association of the R485K polymorphism of the factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population [In Process Citation]. Clin Genet 2000;57:296-303.

160. Iacoviello L, Di Castelnuovo A, De Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998;338:79-85.

161. Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992;339:693-696.

162. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998;92:2771-2776.

163. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 2000;14:791-796.

164. Yamada S, Akita H, Kanazawa K, Ishida T, Hirata K, Ito K, Kawashima S, Yokoyama M. T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction. Atherosclerosis 2000;150:143-148.

165. Baroni MG, D'Andrea MP, Montali A, Pannitteri G, Barilla F, Campagna F, Mazzei E, Lovari S, Seccareccia F, Campa PP, Ricci G, Pozzilli P, Urbinati G, Arca M. A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:2975-2980.

166. Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999;353:351-354.

167. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-1094.

168. Thorn JA, Chamberlain JC, Alcolado JC, Oka K, Chan L, Stocks J, Galton DJ. Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis. Atherosclerosis 1990;85:55-60.

169. Terashima M, Akita H, Kanazawa K, Inoue N, Yamada S, Ito K, Matsuda Y, Takai E, Iwai C, Kurogane H, Yoshida Y, Yokoyama M. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999;99:2717-2719.

11


170. Ichihara S, Yamada Y, Yokota M. Association of a G994-->T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation 1998;98:1881-1885.

171. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, Harada E, Masuda T, Koyama W, Saito Y, Miyamoto Y, Ogawa Y, Nakao K. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998;31:1506-1510.

172. Rutledge DR, Sun Y, Ross EA. Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens 1995;13:953-955.

173. van der Bom JG, de Knijff P, Haverkate F, Bots ML, Meijer P, de Jong PT, Hofman A, Kluft C, Grobbee DE. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997;95:2623-2627.

174. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.

175. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.

176. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease. Cardiovasc Res 1999;44:588-594.

177. Wenzel K, Felix S, Kleber FX, Brachold R, Menke T, Schattke S, Schulte KL, Glaser C, Rohde K, Baumann G, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet 1994;3:1935-1937.

178. Herrmann SM, Ricard S, Nicaud V, Mallet C, Evans A, Ruidavets JB, Arveiler D, Luc G, Cambien F. The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet 1998;7:1277-1284.

179. Ishigami T, Umemura S, Iwamoto T, Tamura K, Hibi K, Yamaguchi S, Nyuui N, Kimura K, Miyazaki N, Ishii M. Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. Circulation 1995;91:951-954.

180. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600-1603.

181. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995;92:1851-1855.

182. Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O. Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996;28:881-887.

183. Norlund L, Holm J, Zoller B, Ohlin AK. A common thrombomodulin amino acid dimorphism is associated with myocardial infarction. Thromb Haemost 1997;77:248-251.

184. Ye L, Miki T, Nakura J, Oshima J, Kamino K, Rakugi H, Ikegami H, Higaki J, Edland SD, Martin GM, Ogihara T. Association of a polymorphic variant of the Werner helicase gene with myocardial infarction in a Japanese population [published erratum appears in Am J Med Genet 1997 May 2;70(1):103]. Am J Med Genet 1997;68:494-498.

185. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999;93:906-908.

12


186. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.

187. Arnaud E, Barbalat V, Nicaud V, Cambien F, Evans A, Morrison C, Arveiler D, Luc G, Ruidavets JB, Emmerich J, Fiessinger JN, Aiach M. Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. Arterioscler Thromb Vasc Biol 2000;20:892-898.

188. Hooper WC, Lally C, Austin H, Renshaw M, Dilley A, Wenger NK, Phillips DJ, Whitsett C, Rawlins P, Evatt BL. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African- American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000;99:223-230.

189. Murata M, Nakagawa M, Takahashi S. Molecular variant of the human paraoxonase/arylesterase gene is associated with central retinal vein occlusion in the Japanese population. Ophthalmologica 1998;212:257-259.

190. Harn HJ, Chang CY, Ho LI, Liu CA, Jeng JR, Lin FG, Jent W. Evidence that polymorphism of the angiotensin I converting enzyme gene may be related to idiopathic dilated cardiomyopathy in the Chinese population. Biochem Mol Biol Int 1995;35:1175-1181.

191. Charron P, Tesson F, Poirier O, Nicaud V, Peuchmaurd M, Tiret L, Cambien F, Amouyel P, Dubourg O, Bouhour J, Millaire A, Juilliere Y, Bareiss P, Andre-Fouet X, Pouillart F, Arveiler D, Ferrieres J, Dorent R, Roizes G, Schwartz K, Desnos M, Komajda M. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. Eur Heart J 1999;20:1587-1591.

192. Hiroi S, Harada H, Nishi H, Satoh M, Nagai R, Kimura A. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem Biophys Res Commun 1999;261:332-339.

193. Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992;184:9-15.

194. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, Nembri P, Amar K, Gatti M, Macciardi F, et al. Association of the alpha-adducin locus with essential hypertension. Hypertension 1995;25:320-326.

195. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-69.

196. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L, Soubrier F. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998;32:198-204.

197. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998;32:3-8.

198. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998;11:125-128.

13


199. Sato M, Soma M, Nakayama T, Kanmatsuse K. Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 2000;36:183-186.

200. Chiang FT, Chiu KC, Tseng YZ, Lee KC, Chuang LM. Nucleotide(-258) G-to-A transition variant of the liver glucokinase gene is associated with essential hypertension. Am J Hypertens 1997;10:1049-1052.

201. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, Lloyd DD, Brown MJ. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999;34:8-14.

202. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998;18:45-48.

203. Schalin-Jantti C, Nikula-Ijas P, Huang X, Lehto M, Knudsen P, Syvanne M, Lehtovirta MT, Tikkanen T, Tikkanen I, Groop LC. Polymorphism of the glycogen synthase gene in hypertensive and normotensive subjects. Hypertension 1996;27:67-71.

204. Watson B, Jr., Bergman SM, Myracle A, Callen DF, Acton RT, Warnock DG. Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 1996;28:478-482.

205. Ying LH, Zee RY, Griffiths LR, Morris BJ. Association of a RFLP for the insulin receptor gene, but not insulin, with essential hypertension. Biochem Biophys Res Commun 1991;181:486-492.

206. Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, Takiuchi S, Rakugi H, Miki T, Higaki J, Ogihara T. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. Am J Hypertens 1998;11:1019-1023.

207. Frossard PM, Lestringant GG, Malloy MJ, Kane JP. Human renin gene BglI dimorphism associated with hypertension in two independent populations. Clin Genet 1999;56:428-433.

208. Iwai N, Ohmichi N, Hanai K, Nakamura Y, Kinoshita M. Human SA gene locus as a candidate locus for essential hypertension. Hypertension 1994;23:375-380.

209. Baker EH, Dong YB, Sagnella GA, Rothwell M, Onipinla AK, Markandu ND, Cappuccio FP, Cook DG, Persu A, Corvol P, Jeunemaitre X, Carter ND, MacGregor GA. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet 1998;351:1388-1392.

210. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992;71:169-180.

211. Sharma P, Hingorani A, Jia H, Ashby M, Hopper R, Clayton D, Brown MJ. Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension 1998;32:676-682.

212. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998;102:1534-1539.

213. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999;99:1422-1425.

214. Ando I, Kukita A, Soma G, Hino H. A large number of tandem repeats in the polymorphic epithelial mucin gene is associated with severe acne. J Dermatol 1998;25:150-152.

14


215. Westphal GA, Reich K, Schulz TG, Neumann C, Hallier E, Schnuch A. N-acetyltransferase 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol 2000;142:1121-1127.

216. Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, Enomoto T, Hashimoto T, Furuyama J, Hopkin JM, Morimoto K. Association between genetic variants of mast-cell chymase and eczema [published erratum appears in Lancet 1997 Jan 4;349(9044):64]. Lancet 1996;348:581-583.

217. Wyatt RJ, Wang C, Hudson EC, Jones RM, Noah PW, Rosenberg EW. Complement phenotypes in patients with psoriasis. Hum Hered 1989;39:327-332.

218. Allen MH, Veal C, Faassen A, Powis SH, Vaughan RW, Trembath RC, Barker JN. A non-HLA gene within the MHC in psoriasis [letter]. Lancet 1999;353:1589-1590.

219. Vasku V, Vasku A, Izakovicova Holla L, Tschoplova S, Kankova K, Benakova N, Semradova V. Polymorphisms in inflammation genes (angiotensinogen, TAP1 and TNF-beta) in psoriasis. Arch Dermatol Res 2000;292:531-534.

220. Gonzalez S, Martinez-Borra J, Del Rio JS, Santos-Juanes J, Lopez-Vazquez A, Blanco-Gelaz M, Lopez-Larrea C. The OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602. J Invest Dermatol 2000;115:824-828.

221. Hohler T, Weinmann A, Schneider PM, Rittner C, Schopf RE, Knop J, Hasenclever P, Meyer zum Buschenfelde KH, Marker-Hermann E. TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis. Hum Immunol 1996;51:49-54.

222. Arias AI, Giles B, Eiermann TH, Sterry W, Pandey JP. Tumor necrosis factor-alpha gene polymorphism in psoriasis. Exp Clin Immunogenet 1997;14:118-122.

223. Hohler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, Meyer zum Buschenfelde KH, Marker-Hermann E. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997;109:562-565.

224. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol 1999;112:113-116.

225. Kemp EH, Ajjan RA, Husebye ES, Peterson P, Uibo R, Imrie H, Pearce SH, Watson PF, Weetman AP. A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clin Endocrinol (Oxf) 1998;49:609-613.

226. Ober C, Xiang KS, Thisted RA, Indovina KA, Wason CJ, Dooley S. Increased risk for gestational diabetes mellitus associated with insulin receptor and insulin-like growth factor II restriction fragment length polymorphisms. Genet Epidemiol 1989;6:559-569.

227. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995;80:41-45.

228. Siegmund T, Usadel KH, Donner H, Braun J, Walfish PG, Badenhoop K. Interferon-gamma gene microsatellite polymorphisms in patients with Graves' disease. Thyroid 1998;8:1013-1017.

229. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI. Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 2000;85:1984-1988.

230. Rau H, Nicolay A, Usadel KH, Finke R, Donner H, Walfish PG, Badenhoop K. Polymorphisms of TAP1 and TAP2 genes in Graves' disease. Tissue Antigens 1997;49:16-22.

231. Tassi V, Scarnecchia L, Di Cerbo A, Pirro MT, Di Paola R, Liuzzi A, Torlontano M, Zingrillo M, D'Aloiso L, De Filippis V. A thyroid hormone receptor beta gene polymorphism associated with Graves' disease. J Mol Endocrinol 1995;15:267-272.

15


232. Sale MM, Akamizu T, Howard TD, Yokota T, Nakao K, Mori T, Iwasaki H, Rich SS, Jennings-Gee JE, Yamada M, Bowden DW. Association of autoimmune thyroid disease with a microsatellite marker for the thyrotropin receptor gene and CTLA-4 in a Japanese population. Proc Assoc Am Physicians 1997;109:453-461.

233. Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 2000;10:375-380.

234. Carling T, Kindmark A, Hellman P, Lundgren E, Ljunghall S, Rastad J, Akerstrom G, Melhus H. Vitamin D receptor genotypes in primary hyperparathyroidism. Nat Med 1995;1:1309-1311.

235. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997;82:3777-3782.

236. Ramanujam LN, Liao WX, Roy AC, Ng SC. Association of molecular variants of luteinizing hormone with male infertility. Hum Reprod 2000;15:925-928.

237. Hani EH, Clement K, Velho G, Vionnet N, Hager J, Philippi A, Dina C, Inoue H, Permutt MA, Basdevant A, North M, Demenais F, Guy-Grand B, Froguel P. Genetic studies of the sulfonylurea receptor gene locus in NIDDM and in morbid obesity among French Caucasians. Diabetes 1997;46:688-694.

238. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L, Arner P. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997;100:3005-3013.

239. Kadowaki H, Yasuda K, Iwamoto K, Otabe S, Shimokawa K, Silver K, Walston J, Yoshinaga H, Kosaka K, Yamada N, et al. A mutation in the beta 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun 1995;215:555-560.

240. Rajput-Williams J, Knott TJ, Wallis SC, Sweetnam P, Yarnell J, Cox N, Bell GI, Miller NE, Scott J. Variation of apolipoprotein-B gene is associated with obesity, high blood cholesterol levels, and increased risk of coronary heart disease. Lancet 1988;2:1442-1446.

241. Vijayaraghavan S, Hitman GA, Kopelman PG. Apolipoprotein-D polymorphism: a genetic marker for obesity and hyperinsulinemia. J Clin Endocrinol Metab 1994;79:568-570.

242. Siffert W, Forster P, Jockel KH, Mvere DA, Brinkmann B, Naber C, Crookes R, Du PHA, Epplen JT, Fridey J, Freedman BI, Muller N, Stolke D, Sharma AM, Al Moutaery K, Grosse-Wilde H, Buerbaum B, Ehrlich T, Ahmad HR, Horsthemke B, Du Toit ED, Tiilikainen A, Ge J, Wang Y, Rosskopf D, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999;10:1921-1930.

243. Rutherford S, Nyholt DR, Curtain RP, Quinlan SR, Gaffney PT, Morris BJ, Griffiths LR. Association of a low density lipoprotein receptor microsatellite variant with obesity. Int J Obes Relat Metab Disord 1997;21:1032-1037.

244. Li WD, Reed DR, Lee JH, Xu W, Kilker RL, Sodam BR, Price RA. Sequence variants in the 5' flanking region of the leptin gene are associated with obesity in women. Ann Hum Genet 1999;63:227-234.

245. Klannemark M, Orho M, Langin D, Laurell H, Holm C, Reynisdottir S, Arner P, Groop L. The putative role of the hormone-sensitive lipase gene in the pathogenesis of Type II diabetes mellitus and abdominal obesity. Diabetologia 1998;41:1516-1522.

246. Oeffner F, Bornholdt D, Ziegler A, Hinney A, Gorg T, Gerber G, Goldschmidt HP, Siegfried W, Wright A, Hebebrand J, Grzeschik KH. Significant association between a silent

16


polymorphism in the neuromedin B gene and body weight in German children and adolescents. Acta Diabetol 2000;37:93-101.

247. Jenkinson CP, Cray K, Walder K, Herzog H, Hanson, Ravussin E. Novel polymorphisms in the neuropeptide-Y Y5 receptor associated with obesity in Pima Indians. Int J Obes Relat Metab Disord 2000;24:580-584.

248. Li WD, Lee JH, Price RA. The peroxisome proliferator-activated receptor gamma 2 Pro12Ala mutation is associated with early onset extreme obesity and reduced fasting glucose. Mol Genet Metab 2000;70:159-161.

249. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, Ruidavets JB, Luc G, Bara L, Parra HJ, Poirier O, Cambien F. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998;28:59-66.

250. Grant SF, Reid DM, Blake G, Herd R, Fogelman I, Ralston SH. Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. Nat Genet 1996;14:203-205.

251. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 1997;20:289-294.

252. Yanagi H, Tomura S, Kawanami K, Hosokawa M, Tanaka M, Kobayashi K, Tsuchiya S, Amagai H, Hayashi K, Hamaguchi H. Vitamin D receptor gene polymorphisms are associated with osteoporosis in Japanese women [letter; comment]. J Clin Endocrinol Metab 1996;81:4179-4181.

253. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S, Williamson R. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.

254. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-1876.

255. Tong Y, Liao WX, Roy AC, Ng SC. Association of AccI polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril 2000;74:1233-1236.

256. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF 3rd, Spielman RS, Dunaif A. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci U S A 1999;96:8573-8578.

257. Waterworth DM, Bennett ST, Gharani N, McCarthy MI, Hague S, Batty S, Conway GS, White D, Todd JA, Franks S, Williamson R. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997;349:986-990.

258. Ramanujam LN, Liao WX, Roy AC, Loganath A, Goh HH, Ng SC. Association of molecular variants of luteinizing hormone with menstrual disorders. Clin Endocrinol (Oxf) 1999;51:243-246.

259. Miyake H, Nagashima K, Onigata K, Nagashima T, Takano Y, Morikawa A. Allelic variations of the D2 dopamine receptor gene in children with idiopathic short stature. J Hum Genet 1999;44:26-29.

260. Minamitani K, Takahashi Y, Minagawa M, Yasuda T, Niimi H. Difference in height associated with a translation start site polymorphism in the vitamin D receptor gene. Pediatr Res 1998;44:628-632.

17


261. Tao C, Yu T, Garnett S, Briody J, Knight J, Woodhead H, Cowell CT. Vitamin D receptor alleles predict growth and bone density in girls. Arch Dis Child 1998;79:488-493; discussion 493-484.

262. Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998;103:435-440.

263. Lhotta K, Auinger M, Kronenberg F, Irsigler K, Konig P. Polymorphism of complement C4 and susceptibility to IDDM and microvascular complications. Diabetes Care 1996;19:53-55.

264. Szalai C, Csaszar A, Czinner A, Szabo T, Panczel P, Madacsy L, Falus A. Chemokine receptor CCR2 and CCR5 polymorphisms in children with insulin-dependent diabetes mellitus. Pediatr Res 1999;46:82-84.

265. Ghabanbasani MZ, Buyse I, Legius E, Decorte R, Marynen P, Bouillon R, Cassiman JJ. Possible association of CD3 and CD4 polymorphisms with insulin-dependent diabetes mellitus (IDDM). Clin Exp Immunol 1994;97:517-521.

266. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E, Larrad MT, Rios MS, Chow CC, Cockram CS, Jacobs K, Mijovic C, Bain SC, Barnett AH, Vandewalle CL, Schuit F, Gorus FK, Tosi R, Pozzilli P, Todd JA. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996;5:1075-1080.

267. Rowe RE, Wapelhorst B, Bell GI, Risch N, Spielman RS, Concannon P. Linkage and association between insulin-dependent diabetes mellitus (IDDM) susceptibility and markers near the glucokinase gene on chromosome 7. Nat Genet 1995;10:240-242.

268. Nishimura M, Obayashi H, Maruya E, Ohta M, Tegoshi H, Fukui M, Hasegawa G, Shigeta H, Kitagawa Y, Nakano K, Saji H, Nakamura N. Association between type 1 diabetes age-at-onset and intercellular adhesion molecule-1 (ICAM-1) gene polymorphism. Hum Immunol 2000;61:507-510.

269. Kristiansen OP, Nolsoe RL, Holst H, Reker S, Larsen ZM, Johannesen J, Nerup J, Pociot F, Mandrup-Poulsen T. The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics 2000;52:107-111.

270. Awata T, Matsumoto C, Urakami T, Hagura R, Amemiya S, Kanazawa Y. Association of polymorphism in the interferon gamma gene with IDDM. Diabetologia 1994;37:1159-1162.

271. Veijola R, Knip M, Puukka R, Reijonen H, Cox DW, Ilonen J. The immunoglobulin heavy-chain variable region in insulin-dependent diabetes mellitus: affected-sib-pair analysis and association studies. Am J Hum Genet 1996;59:462-470.

272. Jahromi MM, Millward BA, Demaine AG. A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. J Interferon Cytokine Res 2000;20:885-888.

273. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984;33:176-183.

274. Pociot F, Molvig J, Wogensen L, Worsaae H, Dalboge H, Baek L, Nerup J. A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 1991;33:37-49.

275. Iwata I, Nagafuchi S, Nakashima H, Kondo S, Koga T, Yokogawa Y, Akashi T, Shibuya T, Umeno Y, Okeda T, Shibata S, Kono S, Yasunami M, Ohkubo H, Niho Y. Association of polymorphism in the NeuroD/BETA2 gene with type 1 diabetes in the Japanese. Diabetes 1999;48:416-419.

18


276. Deng GY, Muir A, Maclaren NK, She JX. Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet 1995;56:528-534.

277. McDermott MF, Ramachandran A, Ogunkolade BW, Aganna E, Curtis D, Boucher BJ, Snehalatha C, Hitman GA. Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians. Diabetologia 1997;40:971-975.

278. Awata T, Inoue K, Kurihara S, Ohkubo T, Inoue I, Abe T, Takino H, Kanazawa Y, Katayama S. Missense variations of the gene responsible for Wolfram syndrome (WFS1/wolframin) in Japanese: possible contribution of the Arg456His mutation to type 1 diabetes as a nonautoimmune genetic basis. Biochem Biophys Res Commun 2000;268:612-616.

279. Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, Warren-Perry M, Zhang Y, Millns H, Turner R, Province M, Bryan J, Permutt MA, Aguilar-Bryan L. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes 1996;45:825-831.

280. Hsieh MC, Lin SR, Hsieh TJ, Hsu CH, Chen HC, Shin SJ, Tsai JH. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant 2000;15:1008-1013.

281. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 1999;42:98-101.

282. Yamada K, Ishiyama-Shigemoto S, Ichikawa F, Yuan X, Koyanagi A, Koyama W, Nonaka K. Polymorphism in the 5'-leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocrinol Metab 1999;84:1754-1757.

283. Ghabanbasani MZ, Spaepen M, Buyse I, Legius E, Decorte R, Bex M, Marynen P, Bouillon R, Cassiman JJ. Increased and decreased relative risk for non-insulin-dependent diabetes mellitus conferred by HLA class II and by CD4 alleles. Clin Genet 1995;47:225-230.

284. Ristow M, Giannakidou E, Hebinck J, Busch K, Vorgerd M, Kotzka J, Knebel B, Mueller-Berghaus J, Epplen C, Pfeiffer A, Kahn CR, Doria A, Krone W, Mueller-Wieland D. An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich's ataxia) gene. Diabetes 1998;47:851-854.

285. Gough SC, Saker PJ, Pritchard LE, Merriman TR, Merriman ME, Rowe BR, Kumar S, Aitman T, Barnett AH, Turner RC, et al. Mutation of the glucagon receptor gene and diabetes mellitus in the UK: association or founder effect? Hum Mol Genet 1995;4:1609-1612.

286. Hager J, Hansen L, Vaisse C, Vionnet N, Philippi A, Poller W, Velho G, Carcassi C, Contu L, Julier C, et al. A missense mutation in the glucagon receptor gene is associated with non-insulin-dependent diabetes mellitus. Nat Genet 1995;9:299-304.

287. Chiu KC, Province MA, Permutt MA. Glucokinase gene is genetic marker for NIDDM in American blacks. Diabetes 1992;41:843-849.

288. Chiu KC, Province MA, Dowse GK, Zimmet PZ, Wagner G, Serjeantson S, Permutt MA. A genetic marker at the glucokinase gene locus for type 2 (non-insulin-dependent) diabetes mellitus in Mauritian Creoles. Diabetologia 1992;35:632-638.

289. Groop LC, Kankuri M, Schalin-Jantti C, Ekstrand A, Nikula-Ijas P, Widen E, Kuismanen E, Eriksson J, Franssila-Kallunki A, Saloranta C, et al. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus [published erratum appears in N Engl J Med 1993 Apr 15;328(15):1136]. N Engl J Med 1993;328:10-14.

19


290. Fernandez-Real JM, Vendrell J, Baiget M, Gimferrer E, Ricart W. C282Y and H63D mutations of the hemochromatosis candidate gene in type 2 diabetes. Diabetes Care 1999;22:525-526.

291. Hitman GA, Jowett NI, Williams LG, Humphries S, Winter RM, Galton DJ. Polymorphisms in the 5'-flanking region of the insulin gene and non-insulin-dependent diabetes. Clin Sci (Colch) 1984;66:383-388.

292. Galton DJ, Trembath RC. Genetic variants of the insulin receptor in type II (non-insulin dependent) diabetes mellitus. Biomed Biochim Acta 1988;47:323-327.

293. McClain DA, Henry RR, Ullrich A, Olefsky JM. Restriction-fragment-length polymorphism in insulin-receptor gene and insulin resistance in NIDDM. Diabetes 1988;37:1071-1075.

294. Hani EH, Stoffers DA, Chevre JC, Durand E, Stanojevic V, Dina C, Habener JF, Froguel P. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999;104:R41-48.

295. Sigal RJ, Doria A, Warram JH, Krolewski AS. Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:1657-1659.

296. Hani EH, Boutin P, Durand E, Inoue H, Permutt MA, Velho G, Froguel P. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia 1998;41:1511-1515.

297. Yoshida H, Ohagi S, Sanke T, Furuta H, Furuta M, Nanjo K. Association of the prohormone convertase 2 gene (PCSK2) on chromosome 20 with NIDDM in Japanese subjects. Diabetes 1995;44:389-393.

298. Xia J, Scherer SW, Cohen PT, Majer M, Xi T, Norman RA, Knowler WC, Bogardus C, Prochazka M. A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 1998;47:1519-1524.

299. Doria A, Caldwell JS, Ji L, Reynet C, Rich SS, Weremowicz S, Morton CC, Warram JH, Kahn CR, Krolewski AS. Trinucleotide repeats at the rad locus. Allele distributions in NIDDM and mapping to a 3-cM region on chromosome 16q. Diabetes 1995;44:243-247.

300. Li SR, Baroni MG, Oelbaum RS, Stock J, Galton DJ. Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988;2:368-370.

301. Alcolado JC, Baroni MG, Li SR. Association between a restriction fragment length polymorphism at the liver/islet cell (GluT 2) glucose transporter and familial type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991;34:734-736.

302. Rissanen J, Wang H, Miettinen R, Karkkainen P, Kekalainen P, Mykkanen L, Kuusisto J, Karhapaa P, Niskanen L, Uusitupa M, Laakso M. Variants in the hepatocyte nuclear factor-1alpha and -4alpha genes in Finnish and Chinese subjects with late-onset type 2 diabetes. Diabetes Care 2000;23:1533-1538.

303. Meirhaeghe A, Amouyel P, Helbecque N, Cottel D, Otabe S, Froguel P, Vasseur F. An uncoupling protein 3 gene polymorphism associated with a lower risk of developing Type II diabetes and with atherogenic lipid profile in a French cohort. Diabetologia 2000;43:1424-1428.

304. Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 1998;43:187-189.

305. McManus R, Moloney M, Borton M, Finch A, Chuan YT, Lawlor E, Weir DG, Kelleher D. Association of celiac disease with microsatellite polymorphisms close to the tumor necrosis factor genes. Hum Immunol 1996;45:24-31.

20


306. Han T, Jiang Z, Suo G, Zhang S. Apolipoprotein B-100 gene Xba I polymorphism and cholesterol gallstone disease. Clin Genet 2000;57:304-308.

307. Juvonen T, Savolainen MJ, Kairaluoma MI, Lajunen LH, Humphries SE, Kesaniemi YA. Polymorphisms at the apoB, apoA-I, and cholesteryl ester transfer protein gene loci in patients with gallbladder disease. J Lipid Res 1995;36:804-812.

308. Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. Gastroenterology 1998;115:1045-1048.

309. Over HH, Ulgen S, Tuglular T, Tezel A, Avsar E, Geyik G, Basgul S, Sayhan N, Ulusoy N, Kalayci C, Tozun N. Thrombophilia and inflammatory bowel disease: does factor V mutation have a role? Eur J Gastroenterol Hepatol 1998;10:827-829.

310. Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ, Sinnott PJ, Hutchinson IV. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999;54:386-390.

311. Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, Duff GW. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994;106:637-642.

312. Pokorny RM, Hofmeister A, Galandiuk S, Dietz AB, Cohen ND, Neibergs HL. Crohn's disease and ulcerative colitis are associated with the DNA repair gene MLH1. Ann Surg 1997;225:718-723; discussion 723-715.

313. Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG. Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients with inflammatory bowel disease, and its clinical implications. Gut 1999;45:389-394.

314. Kyo K, Parkes M, Takei Y, Nishimori H, Vyas P, Satsangi J, Simmons J, Nagawa H, Baba S, Jewell D, Muto T, Lathrop GM, Nakamura Y. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. Hum Mol Genet 1999;8:307-311.

315. Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Pena AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1996;103:391-396.

316. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000;47:211-214.

317. Smithies AM, Sargen K, Demaine AG, Kingsnorth AN. Investigation of the interleukin 1 gene cluster and its association with acute pancreatitis. Pancreas 2000;20:234-240.

318. Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 2000;32:538-541.

319. Halmos B, Szalay F, Cserniczky T, Nemesanszky E, Lakatos P, Barlage S, Schmitz G, Romics L, Csaszar A. Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig Dis Sci 2000;45:1091-1095.

320. Aitman TJ, Cooper LD, Norsworthy PJ, Wahid FN, Gray JK, Curtis BR, McKeigue PM, Kwiatkowski D, Greenwood BM, Snow RW, Hill AV, Scott J. Malaria susceptibility and CD36 mutation. Nature 2000;405:1015-1016.

321. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow RW, Berendt AR, Marsh K, Newbold CI. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet 1997;6:1357-1360.

21


322. Burgner D, Xu W, Rockett K, Gravenor M, Charles IG, Hill AV, Kwiatkowski D. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria [letter]. Lancet 1998;352:1193-1194.

323. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-510.

324. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, Goedert JJ, O'Brien TR, Jacobson LP, Kaslow R, Buchbinder S, Vittinghoff E, Vlahov D, Hoots K, Hilgartner MW, O'Brien SJ. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-965.

325. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study [published erratum appears in Science 1996 Nov 15;274(5290):1069]. Science 1996;273:1856-1862.

326. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.

327. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P, Theodorou I, Combadiere C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287:2274-2277.

328. Garred P, Madsen HO, Balslev U, Hofmann B, Pedersen C, Gerstoft J, Svejgaard A. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997;349:236-240.

329. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, Craig FE, O'Connell P, Tryon V, Clark RA, Dolan MJ, Ahuja SK. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-793.

330. Marquet S, Sanchez FO, Arias M, Rodriguez J, Paris SC, Skamene E, Schurr E, Garcia LF. Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection susceptibility. J Infect Dis 1999;180:1521-1525.

331. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell JM. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995;182:1259-1264.

332. Roy S, McGuire W, Mascie-Taylor CG, Saha B, Hazra SK, Hill AV, Kwiatkowski D. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997;176:530-532.

333. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CG, Hill AV. Association of vitamin D receptor genotype with leprosy type. J Infect Dis 1999;179:187-191.

22


334. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998;27:746-750.

335. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group [In Process Citation]. Lancet 1999;354:556-560.

336. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878-880.

337. Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Hagel I, Palenque M, Lynch NR, Goldblatt J, LeSouef PN. Association of polymorphisms in the beta2-adrenoreceptor gene with higher levels of parasitic infection. Hum Genet 1999;104:269-274.

338. Martin J, Calzada JE, Nieto A. Inducible nitric oxide synthase (NOS2) gene polymorphism and parasitic diseases [letter; comment]. Lancet 1999;353:72.

339. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000;55:1023-1027.

340. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330-1334.

341. Mozzato-Chamay N, Mahdi OS, Jallow O, Mabey DC, Bailey RL, Conway DJ. Polymorphisms in candidate genes and risk of scarring trachoma in a Chlamydia trachomatis--endemic population. J Infect Dis 2000;182:1545-1548.

342. Conway DJ, Holland MJ, Bailey RL, Campbell AE, Mahdi OS, Jennings R, Mbena E, Mabey DC. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun 1997;65:1003-1006.

343. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998;338:640-644.

344. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, Turner MW, Summerfield JA. Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 1996;348:1417-1419.

345. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998;111:579-582.

346. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, Trent RJ. Elite endurance athletes and the ACE I allele--the role of genes in athletic performance. Hum Genet 1998;103:48-50.

347. Rothman N, Smith MT, Hayes RB, Traver RD, Hoener B, Campleman S, Li GL, Dosemeci M, Linet M, Zhang L, Xi L, Wacholder S, Lu W, Meyer KB, Titenko-Holland N, Stewart JT, Yin S, Ross D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997;57:2839-2842.

23


348. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11:328-330.

349. Morrell NW, Sarybaev AS, Alikhan A, Mirrakhimov MM, Aldashev AA. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders [letter]. Lancet 1999;353:814.

350. Wetmur JG, Kaya AH, Plewinska M, Desnick RJ. Molecular characterization of the human delta-aminolevulinate dehydratase 2 (ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 1991;49:757-763.

351. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.

352. Merched A, Xia Y, Papadopoulou A, Siest G, Visvikis S. Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neurosci Lett 1998;242:117-119.

353. Wick U, Witt E, Engel W. Restriction fragment length polymorphisms at the apoprotein genes AI, CIII and B-100 and in the 5' flanking region of the insulin gene as possible markers of coronary heart disease. Clin Genet 1995;47:184-190.

354. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L. Apolipoprotein E polymorphism in a healthy Swedish population: variation of allele frequency with age and relation to serum lipid concentrations. Clin Chem 1993;39:2125-2129.

355. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, Taioli E, Sansoni P, Bertolini S, Franceschi C. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol 1997;17:755-759.

356. Klaver CC, Kliffen M, van Duijn CM, Hofman A, Cruts M, Grobbee DE, van Broeckhoven C, de Jong PT. Genetic association of apolipoprotein E with age-related macular degeneration [published erratum appears in Am J Hum Genet 1998 Oct;63(4):1252]. Am J Hum Genet 1998;63:200-206.

357. Kimura K, Isashiki Y, Sonoda S, Kakiuchi-Matsumoto T, Ohba N. Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration. Am J Ophthalmol 2000;130:769-773.

358. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996;6:73-79.

359. Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, Sirota LA, Marcus SE, Greenberg BD, Lucas FRt, Benjamin J, Murphy DL, Hamer DH. A genetic association for cigarette smoking behavior [comment]. Health Psychol 1999;18:7-13.

360. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol 1997;71:596-599.

361. Stein J, Mulliken JB, Stal S, Gasser DL, Malcolm S, Winter R, Blanton SH, Amos C, Seemanova E, Hecht JT. Nonsyndromic cleft lip with or without cleft palate: evidence of linkage to BCL3 in 17 multigenerational families [published erratum appears in Am J Hum Genet 1996 Sep;59(3):744]. Am J Hum Genet 1995;57:257-272.

362. Lidral AC, Romitti PA, Basart AM, Doetschman T, Leysens NJ, Daack-Hirsch S, Semina EV, Johnson LR, Machida J, Burds A, Parnell TJ, Rubenstein JL, Murray JC. Association of MSX1 and TGFB3 with nonsyndromic clefting in humans. Am J Hum Genet 1998;63:557-568.

24


363. Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG. Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci. Am J Hum Genet 1992;51:1377-1385.

364. Ardinger HH, Buetow KH, Bell GI, Bardach J, VanDemark DR, Murray JC. Association of genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. Am J Hum Genet 1989;45:348-353.

365. Tanabe A, Taketani S, Endo-Ichikawa Y, Tokunaga R, Ogawa Y, Hiramoto M. Analysis of the candidate genes responsible for non-syndromic cleft lip and palate in Japanese people. Clin Sci (Colch) 2000;99:105-111.

366. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, Gilfix BM, Rosenblatt DS, Gravel RA, Forbes P, Rozen R. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999;84:151-157.

367. Morrison K, Papapetrou C, Attwood J, Hol F, Lynch SA, Sampath A, Hamel B, Burn J, Sowden J, Stott D, Mariman E, Edwards YH. Genetic mapping of the human homologue (T) of mouse T(Brachyury) and a search for allele association between human T and spina bifida. Hum Mol Genet 1996;5:669-674.

368. Chung E, Curtis D, Chen G, Marsden PA, Twells R, Xu W, Gardiner M. Genetic evidence for the neuronal nitric oxide synthase gene (NOS1) as a susceptibility locus for infantile pyloric stenosis. Am J Hum Genet 1996;58:363-370.

369. Ramet M, Haataja R, Marttila R, Floros J, Hallman M. Association between the surfactant protein A (SP-A) gene locus and respiratory-distress syndrome in the Finnish population. Am J Hum Genet 2000;66:1569-1579.

370. Weber B, Borkhardt A, Stoll-Becker S, Reiss I, Gortner L. Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants. Turk J Pediatr 2000;42:181-185.

371. Feucht M, Fuchs K, Pichlbauer E, Hornik K, Scharfetter J, Goessler R, Fureder T, Cvetkovic N, Sieghart W, Kasper S, Aschauer H. Possible association between childhood absence epilepsy and the gene encoding GABRB3. Biol Psychiatry 1999;46:997-1002.

372. Sander T, Berlin W, Gscheidel N, Wendel B, Janz D, Hoehe MR. Genetic variation of the human mu-opioid receptor and susceptibility to idiopathic absence epilepsy. Epilepsy Res 2000;39:57-61.

373. Sander T, Berlin W, Ostapowicz A, Samochowiec J, Gscheidel N, Hoehe MR. Variation of the genes encoding the human glutamate EAAT2, serotonin and dopamine transporters and susceptibility to idiopathic generalized epilepsy. Epilepsy Res 2000;41:75-81.

374. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B, Jr., Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998;19:357-360.

375. Liao A, Nitsch RM, Greenberg SM, Finckh U, Blacker D, Albert M, Rebeck GW, Gomez-Isla T, Clatworthy A, Binetti G, Hock C, Mueller-Thomsen T, Mann U, Zuchowski K, Beisiegel U, Staehelin H, Growdon JH, Tanzi RE, Hyman BT. Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet 1998;7:1953-1956.

376. Hu J, Miyatake F, Aizu Y, Nakagawa H, Nakamura S, Tamaoka A, Takahash R, Urakami K, Shoji M. Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. Neurosci Lett 1999;277:65-67.

25


377. Hu Q, Kukull WA, Bressler SL, Gray MD, Cam JA, Larson EB, Martin GM, Deeb SS. The human FE65 gene: genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type. Hum Genet 1998;103:295-303.

378. Csaszar A, Kalman J, Szalai C, Janka Z, Romics L. Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci Lett 1997;230:151-154.

379. Kamino K, Yoshiiwa A, Nishiwaki Y, Nagano K, Yamamoto H, Kobayashi T, Nonomura Y, Yoneda H, Sakai T, Imagawa M, Miki T, Ogihara T. Genetic association study between senile dementia of Alzheimer's type and APOE/C1/C2 gene cluster. Gerontology 1996;42 Suppl 1:12-19.

380. Schellenberg GD, Deeb SS, Boehnke M, Bryant EM, Martin GM, Lampe TH, Bird TD. Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J Neurogenet 1987;4:97-108.

381. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.

382. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-1936.

383. Montoya SE, Aston CE, DeKosky ST, Kamboh MI, Lazo JS, Ferrell RE. Bleomycin hydrolase is associated with risk of sporadic Alzheimer's disease [letter] [published erratum appears in Nat Genet 1998 Aug;19(4):404]. Nat Genet 1998;18:211-212.

384. Papassotiropoulos A, Bagli M, Feder O, Jessen F, Maier W, Rao ML, Ludwig M, Schwab SG, Heun R. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease. Neurosci Lett 1999;262:171-174.

385. Tsai SJ, Liu HC, Liu TY, Wang YC, Hong CJ. Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease. Neurosci Lett 1999;276:138-139.

386. Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol 2000;47:365-368.

387. Wavrant-DeVrieze F, Perez-Tur J, Lambert JC, Frigard B, Pasquier F, Delacourte A, Amouyel P, Hardy J, Chartier-Harlin MC. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci Lett 1997;227:68-70.

388. Dahiyat M, Cumming A, Harrington C, Wischik C, Xuereb J, Corrigan F, Breen G, Shaw D, St Clair D. Association between Alzheimer's disease and the NOS3 gene. Ann Neurol 1999;46:664-667.

389. Wragg M, Hutton M, Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet 1996;347:509-512.

390. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat Genet 1995;10:486-488.

391. Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, Lesch KP, Powell J, Lovestone S, Collier D. Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease. Neuroreport 1997;8:683-686.

392. van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of the transferrin C2 subtype in Alzheimer's disease. Neuroreport 1993;4:1269-1271.

393. Lambert JC, Goumidi L, Vrieze FW, Frigard B, Harris JM, Cummings A, Coates J, Pasquier F, Cottel D, Gaillac M, St Clair D, Mann DM, Hardy J, Lendon CL, Amouyel P, Chartier-Harlin

26


MC. The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Hum Mol Genet 2000;9:2275-2280.

394. Luedecking EK, DeKosky ST, Mehdi H, Ganguli M, Kamboh MI. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum Genet 2000;106:565-569.

395. Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, St Clair D, Brookes AJ. apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Hum Genet 2000;107:391-396.

396. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H, Takahashi H, et al. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 1995;11:207-209.

397. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease [published erratum appears in Nature 1991 Aug 8;352(6335):547]. Nature 1991;352:340-342.

398. Steinlein O, Sander T, Stoodt J, Kretz R, Janz D, Propping P. Possible association of a silent polymorphism in the neuronal nicotinic acetylcholine receptor subunit alpha4 with common idiopathic generalized epilepsies. Am J Med Genet 1997;74:445-449.

399. Ma JJ, Nishimura M, Mine H, Kuroki S, Nukina M, Ohta M, Saji H, Obayashi H, Kawakami H, Saida T, Uchiyama T. Genetic contribution of the tumor necrosis factor region in Guillain-Barre syndrome. Ann Neurol 1998;44:815-818.

400. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997;350:1069-1071.

401. Nacmias B, Tedde A, Guarnieri BM, Petruzzi C, Ortenzi L, Serio A, Amaducci L, Sorbi S. Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Neurosci Lett 1997;229:177-180.

402. Takenaka K, Yamakawa H, Sakai H, Yoshimura S, Murase S, Okumura A, Nakatani K, Kimura T, Nishimura Y, Yoshimi N, Sakai N. Angiotensin I-converting enzyme gene polymorphism in intracranial saccular aneurysm individuals. Neurol Res 1998;20:607-611.

403. Takenaka K, Sakai H, Yamakawa H, Yoshimura S, Kumagai M, Nakashima S, Nozawa Y, Sakai N. Polymorphism of the endoglin gene in patients with intracranial saccular aneurysms. J Neurosurg 1999;90:935-938.

404. Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999;30:2612-2616.

405. Markus HS, Barley J, Lunt R, Bland JM, Jeffery S, Carter ND, Brown MM. Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke 1995;26:1329-1333.

406. Ji Y, Urakami K, Adachi Y, Maeda M, Isoe K, Nakashima K. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease. Dement Geriatr Cogn Disord 1998;9:243-245.

407. Ito D, Murata M, Watanabe K, Yoshida T, Saito I, Tanahashi N, Fukuuchi Y. C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000;31:936-939.

27


408. Alberts MJ, Davis JP, Graffagnino C, McClenny C, Delong D, Granger C, Herbstreith MH, Boteva K, Marchuk DA, Roses AD. Endoglin gene polymorphism as a risk factor for sporadic intracerebral hemorrhage. Ann Neurol 1997;41:683-686.

409. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage. Stroke 1998;29:813-816.

410. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-3565.

411. Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, Ikeda U, Shimada K, Matsuo M. Genetic variation in the promoter region of the beta-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinolysis 1998;9:373-379.

412. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT, Jr., Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000;31:1628-1633.

413. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Kitamura K, Yazaki Y. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18:1465-1469.

414. Soriente L, Coppola A, Madonna P, Cerbone AM, Di Minno G, Orefice G, D'Angelo A. Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. Stroke 1998;29:869-871.

415. Elbaz A, Poirier O, Moulin T, Chedru F, Cambien F, Amarenco P. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. The GENIC Investigators. Stroke 2000;31:1634-1639.

416. Rubattu S, Ridker P, Stampfer MJ, Volpe M, Hennekens CH, Lindpaintner K. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999;100:1722-1726.

417. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K. A mutation in plasma platelet-activating factor acetylhydrolase (Val279- ->Phe) is a genetic risk factor for stroke. Stroke 1997;28:2417-2420.

418. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435-442.

419. Lea RA, Dohy A, Jordan K, Quinlan S, Brimage PJ, Griffiths LR. Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 2000;3:35-40.

420. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000;96:762-764.

421. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J. Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia 1998;18:23-26.

422. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999;97:182-190.

28


423. Crusius JB, Pena AS, Van Oosten BW, Bioque G, Garcia A, Dijkstra CD, Polman CH. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 1995;346:979.

424. Boylan KB, Takahashi N, Paty DW, Sadovnick AD, Diamond M, Hood LE, Prusiner SB. DNA length polymorphism 5' to the myelin basic protein gene is associated with multiple sclerosis. Ann Neurol 1990;27:291-297.

425. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert RB, Kantarci O, Schaefer-Klein J, Schipper HI, Oertel WH, Heidenreich F, Weinshenker BG, Sommer N, Hemmer B. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 2000;26:495-499.

426. Raknes G, Skeie GO, Gilhus NE, Aadland S, Vedeler C. FcgammaRIIA and FcgammaRIIIB polymorphisms in myasthenia gravis. J Neuroimmunol 1998;81:173-176.

427. Huang D, Pirskanen R, Hjelmstrom P, Lefvert AK. Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. J Neuroimmunol 1998;81:76-81.

428. Hjelmstrom P, Peacock CS, Giscombe R, Pirskanen R, Lefvert AK, Blackwell JM, Sanjeevi CB. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis. J Neuroimmunol 1998;88:137-143.

429. McKenna MJ, Kristiansen AG, Bartley ML, Rogus JJ, Haines JL. Association of COL1A1 and otosclerosis: evidence for a shared genetic etiology with mild osteogenesis imperfecta. Am J Otol 1998;19:604-610.

430. Kruger R, Menezes-Saecker AM, Schols L, Kuhn W, Muller T, Woitalla D, Berg D, Berger K, Przuntek H, Epplen JT, Riess O. Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. Neuroreport 2000;11:2439-2442.

431. Buervenich S, Sydow O, Carmine A, Zhang Z, Anvret M, Olson L. Alcohol dehydrogenase alleles in Parkinson's disease. Mov Disord 2000;15:813-818.

432. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C, Nakamura T. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet 1999;56:394-399.

433. Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T, Nanko S, Murray RM, McGuffin P, Owen M, Gill M, Collier DA. Catechol-O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiply affected families. Psychiatr Genet 1997;7:97-101.

434. Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I. Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson's disease. J Neural Transm Gen Sect 1996;103:843-849.

435. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.

436. Kobayashi T, Matsumine H, Matuda S, Mizuno Y. Association between the gene encoding the E2 subunit of the alpha-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann Neurol 1998;43:120-123.

437. Plante-Bordeneuve V, Taussig D, Thomas F, Said G, Wood NW, Marsden CD, Harding AE. Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. Neurology 1997;48:1589-1593.

29


438. Ahmadi A, Fredrikson M, Jerregard H, Akerback A, Fall PA, Rannug A, Axelson O, Soderkvist P. GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem Biophys Res Commun 2000;269:676-680.

439. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998;352:1344-1346.

440. Nakatome M, Tun Z, Shimada S, Honda K. Detection and analysis of four polymorphic markers at the human monoamine oxidase (MAO) gene in Japanese controls and patients with Parkinson's disease. Biochem Biophys Res Commun 1998;247:452-456.

441. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-372.

442. Pastor P, Ezquerra M, Munoz E, Marti MJ, Blesa R, Tolosa E, Oliva R. Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann Neurol 2000;47:242-245.

443. Bandmann O, Vaughan J, Holmans P, Marsden CD, Wood NW. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997;350:1136-1139.

444. Sohn YK, Ganju N, Bloch KD, Wands JR, de la Monte SM. Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. J Neurol Sci 1999;162:133-151.

445. Yamamoto M, Kondo I, Ogawa N, Asanuma M, Yamashita Y, Mizuno Y. Genetic association between susceptibility to Parkinson's disease and alpha1-antichymotrypsin polymorphism. Brain Res 1997;759:153-155.

446. Le Couteur DG, Leighton PW, McCann SJ, Pond S. Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Mov Disord 1997;12:760-763.

447. McCann SJ, McManus ME, Johnson AG, Mellick GD, Le Couteur DG, Pond SM. The serotonin transporter gene and Parkinson's disease. Eur Neurol 2000;44:108-111.

448. Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology 2000;54:1195-1198.

449. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999;53:1858-1860.

450. Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I, Lolis D. Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril 1999;72:164-166.

451. Gloria-Bottini F, Nicotra M, Lucarini N, Borgiani P, La Torre M, Amante A, Gimelfarb A, Bottini E. Phosphotyrosine-protein-phosphatases and human reproduction: an association between low molecular weight acid phosphatase (ACP1) and spontaneous abortion. Dis Markers 1996;12:261-269.

452. Tsai AF, Kaufman KA, Walker MA, Karrison TG, Odem RR, Barnes RB, Scott JR, Schreiber JR, Stephenson MD, Ober C. Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage. J Reprod Immunol 1998;40:147-157.

453. Wang X, Wang M, Niu T, Chen C, Xu X. Microsomal epoxide hydrolase polymorphism and risk of spontaneous abortion. Epidemiology 1998;9:540-544.

454. Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida A, Agorastos T, Zournatzi V, Makris PE, Bontis J, Kotsis A. Factor V leiden and prothrombin G20210A mutations, but not

30


methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 2000;15:458-462.

455. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, Scianname N, Pavone G, Di Minno G. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-824.

456. Lissak A, Sharon A, Fruchter O, Kassel A, Sanderovitz J, Abramovici H. Polymorphism for mutation of cytosine to thymine at location 677 in the methylenetetrahydrofolate reductase gene is associated with recurrent early fetal loss. Am J Obstet Gynecol 1999;181:126-130.

457. Morgan L, Crawshaw S, Baker PN, Brookfield JF, Broughton Pipkin F, Kalsheker N. Distortion of maternal-fetal angiotensin II type 1 receptor allele transmission in pre-eclampsia. J Med Genet 1998;35:632-636.

458. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13.

459. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996;175:902-905.

460. Hubel CA, Roberts JM, Ferrell RE. Association of pre-eclampsia with common coding sequence variations in the lipoprotein lipase gene. Clin Genet 1999;56:289-296.

461. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T. Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997;34:525-526.

462. Arngrimsson R, Hayward C, Nadaud S, Baldursdottir A, Walker JJ, Liston WA, Bjarnadottir RI, Brock DJ, Geirsson RT, Connor JM, Soubrier F. Evidence for a familial pregnancy-induced hypertension locus in the eNOS-gene region. Am J Hum Genet 1997;61:354-362.

463. Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, Hamada H, Kubo T, Hamaguchi H. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 2000;45:138-141.

464. Chen G, Wilson R, Wang SH, Zheng HZ, Walker JJ, McKillop JH. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. Clin Exp Immunol 1996;104:154-159.

465. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-3188.

466. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000;11:1893-1897.

467. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ. PlA2 polymorphism and efficacy of aspirin [letter]. Lancet 1998;351:1253.

468. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-718.

469. Shaikh S, Collier DA, Sham PC, Ball D, Aitchison K, Vallada H, Smith I, Gill M, Kerwin RW. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97:714-719.

470. Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ. The major histocompatibility complex region marked by HSP70-1 and HSP70- 2 variants is

31


associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995;86:3835-3840.

471. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995;346:281-282.

472. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW. Association between clozapine response and allelic variation in the 5- HT2C receptor gene. Neuroreport 1995;7:169-172.

473. Yu YW, Tsai SJ, Lin CH, Hsu CP, Yang KH, Hong CJ. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999;10:1231-1233.

474. Turbay D, Lieberman J, Alper CA, Delgado JC, Corzo D, Yunis JJ, Yunis EJ. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997;89:4167-4174.

475. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K, Sieghart W, Aschauer HN, Kasper S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive. Schizophr Res 1998;32:101-106.

476. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T, Abe K. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in. Schizophr Res 1998;32:107-113.

477. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997;41:827-829.

478. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-145.

479. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, Dorevitch A, Yakir A, Lerner A, Goltser T, Shelevoy A, Lerer B. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000;152:408-413.

480. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000;23:170-177.

481. Guzman EC, Hirata MH, Quintao EC, Hirata RD. Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 2000;38:731-736.

482. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511.

483. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan. Cancer Res 2000;60:6921-6926.

484. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [In Process Citation]. Nat Genet 1999;22:168-170.

485. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998;8:259-268.

32


486. Schulz WA, Krummeck A, Rosinger I, Schmitz-Drager BJ, Sies H. Predisposition towards urolithiasis associated with the NQO1 null-allele. Pharmacogenetics 1998;8:453-454.

487. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-1030.

488. Sagar M, Seensalu R, Tybring G, Dahl ML, Bertilsson L. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Scand J Gastroenterol 1998;33:1034-1038.

489. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93.

490. de Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, Kastelein JJ, van Boven AJ, Bruschke AV, Humphries SE, Kluft C, Henney AM. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999;83:852-856.

491. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-12264.

492. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-534.

493. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719.

494. Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa [letter]. Lancet 1997;350:412.

495. Eisenberg J, Mei-Tal G, Steinberg A, Tartakovsky E, Zohar A, Gritsenko I, Nemanov L, Ebstein RP. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am J Med Genet 1999;88:497-502.

496. LaHoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996;1:121-124.

497. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 1999;4:192-196.

498. Cook EH, Jr., Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993-998.

499. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, Basile VS, Beitchman J, Kennedy JL. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). Mol Psychiatry 2000;5:537-541.

500. Barr CL, Feng Y, Wigg K, Bloom S, Roberts W, Malone M, Schachar R, Tannock R, Kennedy JL. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol Psychiatry 2000;5:405-409.

33


501. Persico AM, Militerni R, Bravaccio C, Schneider C, Melmed R, Trillo S, Montecchi F, Palermo MT, Pascucci T, Puglisi-Allegra S, Reichelt KL, Conciatori M, Baldi A, Keller F. Adenosine deaminase alleles and autistic disorder: case-control and family-based association studies. Am J Med Genet 2000;96:784-790.

502. Petit E, Herault J, Martineau J, Perrot A, Barthelemy C, Hameury L, Sauvage D, Lelord G, Muh JP. Association study with two markers of a human homeogene in infantile autism. J Med Genet 1995;32:269-274.

503. Vincent JB, Konecki DS, Munstermann E, Bolton P, Poustka A, Poustka F, Gurling HM. Point mutation analysis of the FMR-1 gene in autism. Mol Psychiatry 1996;1:227-231.

504. Bellivier F, Laplanche JL, Schurhoff F, Feingold J, Feline A, Jouvent R, Launay JM, Leboyer M. Apolipoprotein E gene polymorphism in early and late onset bipolar patients. Neurosci Lett 1997;233:45-48.

505. Mynett-Johnson L, Murphy V, McCormack J, Shields DC, Claffey E, Manley P, McKeon P. Evidence for an allelic association between bipolar disorder and a Na+, K+ adenosine triphosphatase alpha subunit gene (ATP1A3). Biol Psychiatry 1998;44:47-51.

506. Li T, Vallada H, Curtis D, Arranz M, Xu K, Cai G, Deng H, Liu J, Murray R, Liu X, Collier DA. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics 1997;7:349-353.

507. Borglum AD, Bruun TG, Kjeldsen TE, Ewald H, Mors O, Kirov G, Russ C, Freeman B, Collier DA, Kruse TA. Two novel variants in the DOPA decarboxylase gene: association with bipolar affective disorder. Mol Psychiatry 1999;4:545-551.

508. Parsian A, Chakraverty S, Todd RD. Possible association between the dopamine D3 receptor gene and bipolar affective disorder. Am J Med Genet 1995;60:234-237.

509. Papadimitriou GN, Dikeos DG, Karadima G, Avramopoulos D, Daskalopoulou EG, Vassilopoulos D, Stefanis CN. Association between the GABA(A) receptor alpha5 subunit gene locus (GABRA5) and bipolar affective disorder. Am J Med Genet 1998;81:73-80.

510. Birkett JT, Arranz MJ, Munro J, Osbourn S, Kerwin RW, Collier DA. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000;11:2017-2020.

511. Vogt IR, Shimron-Abarbanell D, Neidt H, Erdmann J, Cichon S, Schulze TG, Muller DJ, Maier W, Albus M, Borrmann-Hassenbach M, Knapp M, Rietschel M, Propping P, Nothen MM. Investigation of the human serotonin 6 [5-HT6] receptor gene in bipolar affective disorder and schizophrenia. Am J Med Genet 2000;96:217-221.

512. Lim LC, Powell J, Sham P, Castle D, Hunt N, Murray R, Gill M. Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am J Med Genet 1995;60:325-331.

513. Parsian A, Todd RD. Genetic association between monoamine oxidase and manic-depressive illness: comparison of relative risk and haplotype relative risk data. Am J Med Genet 1997;74:475-479.

514. Dawson E, Gill M, Curtis D, Castle D, Hunt N, Murray R, Powell J. Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder. Psychiatr Genet 1995;5:177-180.

515. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B, Berghofer A, Muller-Oerlinghausen B, Dvorakova M, Libigerova E, Vojtechovsky M, Zvolsky P, Joober R, Nilsson A, Prochazka H, Licht RW, Rasmussen NA, Schou M, Vestergaard P, Holzinger A, Schumann

34


C, Thau K, Rouleau GA, Alda M. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998;3:534-538.

516. Meira-Lima IV, Pereira AC, Mota GF, Krieger JE, Vallada H. Angiotensinogen and angiotensin converting enzyme gene polymorphisms and the risk of bipolar affective disorder in humans. Neurosci Lett 2000;293:103-106.

517. Collier DA, Arranz MJ, Sham P, Battersby S, Vallada H, Gill P, Aitchison KJ, Sodhi M, Li T, Roberts GW, Smith B, Morton J, Murray RM, Smith D, Kirov G. The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. Neuroreport 1996;7:1675-1679.

518. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, Allilaire JF, Feingold J, Mallet J, Malafosse A. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry 1998;55:33-37.

519. Comings DE, Rosenthal RJ, Lesieur HR, Rugle LJ, Muhleman D, Chiu C, Dietz G, Gade R. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996;6:223-234.

520. Perez de Castro I, Ibanez A, Torres P, Saiz-Ruiz J, Fernandez-Piqueras J. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 1997;7:345-348.

521. Arinami T, Li L, Mitsushio H, Itokawa M, Hamaguchi H, Toru M. An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders. Biol Psychiatry 1996;40:1122-1127.

522. Ohara K, Nagai M, Suzuki Y. Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport 1998;9:1305-1308.

523. Dikeos DG, Papadimitriou GN, Avramopoulos D, Karadima G, Daskalopoulou EG, Souery D, Mendlewicz J, Vassilopoulos D, Stefanis CN. Association between the dopamine D3 receptor gene locus (DRD3) and unipolar affective disorder. Psychiatr Genet 1999;9:189-195.

524. Manki H, Kanba S, Muramatsu T, Higuchi S, Suzuki E, Matsushita S, Ono Y, Chiba H, Shintani F, Nakamura M, Yagi G, Asai M. Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. J Affect Disord 1996;40:7-13.

525. Battersby S, Ogilvie AD, Smith CA, Blackwood DH, Muir WJ, Quinn JP, Fink G, Goodwin GM, Harmar AJ. Structure of a variable number tandem repeat of the serotonin transporter. Psychiatr Genet 1996;6:177-181.

526. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, Goldman D, Linnoila M. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch Gen Psychiatry 1998;55:593-602.

527. Billett EA, Richter MA, Sam F, Swinson RP, Dai XY, King N, Badri F, Sasaki T, Buchanan JA, Kennedy JL. Investigation of dopamine system genes in obsessive-compulsive disorder. Psychiatr Genet 1998;8:163-169.

528. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry 2000;157:1160-1161.

529. Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D. 5-HT2A promoter polymorphism -1438G/A, anorexia nervosa, and obsessive-compulsive disorder [letter]. Lancet 1998;351:1785-1786.

530. McDougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 1998;3:270-273.

35


531. Deckert J, Nothen MM, Franke P, Delmo C, Fritze J, Knapp M, Maier W, Beckmann H, Propping P. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry 1998;3:81-85.

532. Wang Z, Valdes J, Noyes R, Zoega T, Crowe RR. Possible association of a cholecystokinin promotor polymorphism (CCK- 36CT) with panic disorder. Am J Med Genet 1998;81:228-234.

533. Harrington CR, Roth M, Xuereb JH, McKenna PJ, Wischik CM. Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995;202:101-104.

534. Tachikawa H, Harada S, Kawanishi Y, Okubo T, Shiraishi H. Novel polymorphisms of the human cholecystokinin A receptor gene: an association analysis with schizophrenia. Am J Med Genet 2000;96:141-145.

535. Tachikawa H, Harada S, Kawanishi Y, Okubo T, Shiraishi H. Novel polymorphism in the promoter and coding regions of the human cholecystokinin B receptor gene: an association analysis with schizophrenia. Am J Med Genet 1999;88:700-704.

536. Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM, Liu X, Collier DA. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 1996;6:131-133.

537. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997;6:577-582.

538. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC, et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992;29:858-860.

539. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 1999;258:292-295.

540. Williams NM, Cardno AG, Murphy KC, Jones LA, Asherson P, McGuffin P, Owen MJ. Association between schizophrenia and a microsatellite polymorphism at the dopamine D5 receptor gene. Psychiatr Genet 1997;7:83-85.

541. Schwab SG, Hallmayer J, Lerer B, Albus M, Borrmann M, Honig S, Strauss M, Segman R, Lichtermann D, Knapp M, Trixler M, Maier W, Wildenauer DB. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am J Hum Genet 1998;63:1139-1152.

542. Sanders AR, Rincon-Limas DE, Chakraborty R, Grandchamp B, Hamilton JD, Fann WE, Patel PI. Association between genetic variation at the porphobilinogen deaminase. Schizophr Res 1993;8:211-221.

543. Orange PR, Heath PR, Wright SR, Ramchand CN, Kolkeiwicz L, Pearson RC. Individuals with schizophrenia have an increased incidence of the H2R649G allele for the histamine H2 receptor gene. Mol Psychiatry 1996;1:466-469.

544. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. Association between schizophrenia and T102C polymorphism of the 5- hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 1996;347:1294-1296.

545. Tsai SJ, Chiu HJ, Wang YC, Hong CJ. Association study of serotonin-6 receptor variant (C267T) with schizophrenia and aggressive behavior. Neurosci Lett 1999;271:135-137.

36


546. Bowen T, Guy CA, Craddock N, Cardno AG, Williams NM, Spurlock G, Murphy KC, Jones LA, Gray M, Sanders RD, McCarthy G, Chandy KG, Fantino E, Kalman K, Gutman GA, Gargus JJ, Williams J, McGuffin P, Owen MJ, O'Donovan MC. Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia. Mol Psychiatry 1998;3:266-269.

547. Nanko S, Hattori M, Kuwata S, Sasaki T, Fukuda R, Dai XY, Yamaguchi K, Shibata Y, Kazamatsuri H. Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr Scand 1994;89:390-392.

548. Ishiguro H, Ohtsuki T, Toru M, Itokawa M, Aoki J, Shibuya H, Kurumaji A, Okubo Y, Iwawaki A, Ota K, Shimizu H, Hamaguchi H, Arinami T. Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia. Neurosci Lett 1998;257:45-48.

549. Hudson CJ, Kennedy JL, Gotowiec A, Lin A, King N, Gojtan K, Macciardi F, Skorecki K, Meltzer HY, Warsh JJ, Horrobin DF. Genetic variant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr Res 1996;21:111-116.

550. Bell R, Collier DA, Rice SQ, Roberts GW, MacPhee CH, Kerwin RW, Price J, Gloger IS. Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem Biophys Res Commun 1997;241:630-635.

551. Bell R, Munro J, Russ C, Powell JF, Bruinvels A, Kerwin RW, Collier DA. Systematic screening of the 14-3-3 eta (eta) chain gene for polymorphic variants and case-control analysis in schizophrenia. Am J Med Genet 2000;96:736-743.

552. Benessiano J, Crestani B, Mestari F, Klouche W, Neukirch F, Hacein-Bey S, Durand G, Aubier M. High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma. J Allergy Clin Immunol 1997;99:53-57.

553. Hopes E, McDougall C, Christie G, Dewar J, Wheatley A, Hall IP, Helms PJ. Association of glutamine 27 polymorphism of beta 2 adrenoceptor with reported childhood asthma: population based study. BMJ 1998;316:664.

554. Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ. Association of CCR5 delta32 with reduced risk of asthma [letter]. Lancet 1999;354:1264-1265.

555. Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. DeltaF508 heterozygosity in cystic fibrosis and susceptibility to asthma [published erratum appears in Lancet 1998 Oct 10;352(9135):1230]. Lancet 1998;351:1911-1913.

556. Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC, Spiteri MA. Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma. Am J Respir Crit Care Med 2000;161:1437-1442.

557. Yan L, Galinsky RE, Bernstein JA, Liggett SB, Weinshilboum RM. Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. Pharmacogenetics 2000;10:261-266.

558. Lim S, Crawley E, Woo P, Barnes PJ. Haplotype associated with low interleukin-10 production in patients with severe asthma [letter]. Lancet 1998;352:113.

559. van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, Bakker A, Verweij CL, Aarden LA, van der Zee JS. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1999;1:61-65.

560. Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, Yanagi H, Matsui A, Hamaguchi H. Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy 1998;28:449-453.

37


561. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997;337:1720-1725.

562. Kauppi P, Laitinen T, Ollikainen V, Mannila H, Laitinen LA, Kere J. The IL9R region contribution in asthma is supported by genetic association in an isolated population. Eur J Hum Genet 2000;8:788-792.

563. Moffatt MF, Cookson WO. Tumour necrosis factor haplotypes and asthma. Hum Mol Genet 1997;6:551-554.

564. Shirakawa T, Li A, Dubowitz M, Dekker JW, Shaw AE, Faux JA, Ra C, Cookson WO, Hopkin JM. Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor. Nat Genet 1994;7:125-129.

565. Grasemann H, Yandava CN, Drazen JM. Neuronal NO synthase (NOS1) is a major candidate gene for asthma. Clin Exp Allergy 1999;29 Suppl 4:39-41.

566. Lee YC, Cheon KT, Lee HB, Kim W, Rhee YK, Kim DS. Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with asthma. Allergy 2000;55:959-963.

567. Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 2000;66:1522-1530.

568. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC, Makki R, Tavernier G, Smilie FI, Custovic A, Woodcock AA, Ollier WE, Hajeer AH. The -403 G-->A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun 2000;1:509-514.

569. Holla L, Vasku A, Znojil V, Siskova L, Vacha J. Association of 3 gene polymorphisms with atopic diseases. J Allergy Clin Immunol 1999;103:702-708.

570. Ismail A, Bousaffara R, Kaziz J, Zili J, el Kamel A, Tahar Sfar M, Remadi S, Chouchane L. Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians. J Allergy Clin Immunol 1997;99:216-223.

571. Silvennoinen-Kassinen S, Ikaheimo I, Tiilikainen A. TAP1 and TAP2 genes in nickel allergy. Int Arch Allergy Immunol 1997;114:94-96.

572. Unoki M, Furuta S, Onouchi Y, Watanabe O, Doi S, Fujiwara H, Miyatake A, Fujita K, Tamari M, Nakamura Y. Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 2000;106:440-446.

573. Laing IA, Goldblatt J, Eber E, Hayden CM, Rye PJ, Gibson NA, Palmer LJ, Burton PR, Le Souef PN. A polymorphism of the CC16 gene is associated with an increased risk of asthma. J Med Genet 1998;35:463-467.

574. Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gile LS, Luisetti M, Pignatti PF. Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet 1998;103:718-722.

575. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350:630-633.

576. Schellenberg D, Pare PD, Weir TD, Spinelli JJ, Walker BA, Sandford AJ. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998;157:957-961.

38


577. Ishii T, Matsuse T, Teramoto S, Matsui H, Miyao M, Hosoi T, Takahashi H, Fukuchi Y, Ouchi Y. Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax 1999;54:693-696.

578. Kalsheker NA, Hodgson IJ, Watkins GL, White JP, Morrison HM, Stockley RA. Deoxyribonucleic acid (DNA) polymorphism of the alpha 1-antitrypsin gene in chronic lung disease. Br Med J (Clin Res Ed) 1987;294:1511-1514.

579. Ishii T, Matsuse T, Teramoto S, Matsui H, Hosoi T, Fukuchi Y, Ouchi Y. Association between alpha-1-antichymotrypsin polymorphism and susceptibility to chronic obstructive pulmonary disease. Eur J Clin Invest 2000;30:543-548.

580. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997;156:1436-1439.

581. Zhai R, Jetten M, Schins RP, Franssen H, Borm PJ. Polymorphisms in the promoter of the tumor necrosis factor-alpha gene in coal miners. Am J Ind Med 1998;34:318-324.

582. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-1020.

583. Carter AM, Catto AJ, Kohler HP, Ariens RA, Stickland MH, Grant PJ. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000;96:1177-1179.

584. Maliarik MJ, Rybicki BA, Malvitz E, Sheffer RG, Major M, Popovich J, Jr., Iannuzzi MC. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998;158:1566-1570.

585. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 1999;159:2021-2023.

586. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl E, Du Bois R. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000;162:1000-1003.

587. Maliarik MJ, Chen KM, Sheffer RG, Rybicki BA, Major ML, Popovich J, Jr., Iannuzzi MC. The natural resistance-associated macrophage protein gene in African Americans with sarcoidosis. Am J Respir Cell Mol Biol 2000;22:672-675.

588. Niimi T, Tomita H, Sato S, Kawaguchi H, Akita K, Maeda H, Sugiura Y, Ueda R. Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med 1999;160:1107-1109.

589. Li PK, Poon P, Phil M, Poon AS, Szeto CC, Yu AW, Lai KN. Association of IgA nephropathy with T-cell receptor constant alpha chain gene polymorphism. Am J Kidney Dis 1997;30:260-264.

590. Halkas AC, Gaillard MC, Thomson PD, Green SL, Ludewick H, Kala U. Variants of alpha 1-proteinase inhibitor in black and white South African patients with focal glomerulosclerosis and minimal change nephrotic syndrome. J Med Genet 1998;35:6-9.

591. Bachvarov DR, Landry M, Pelletier I, Chevrette M, Betard C, Houde I, Bergeron J, Lebel M, Marceau F. Characterization of two polymorphic sites in the human kinin B1 receptor gene: altered frequency of an allele in patients with a history of end-stage renal failure. J Am Soc Nephrol 1998;9:598-604.

39


592. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E. Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int 2000;58:513-519.

593. Smolenicka Z, Bach E, Schaer A, Liechti-Gallati S, Frey BM, Frey FJ, Ferrari P. A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 1998;83:1814-1817.

594. Yu H, Bowden DW, Spray BJ, Rich SS, Freedman BI. Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 1998;31:906-911.

595. Wang Y, Kikuchi S, Suzuki H, Nagase S, Koyama A. Endothelial nitric oxide synthase gene polymorphism in intron 4 affects the progression of renal failure in non-diabetic renal diseases. Nephrol Dial Transplant 1999;14:2898-2902.

596. Verity DH, Vaughan RW, Kondeatis E, Madanat W, Zureikat H, Fayyad F, Marr JE, Kanawati CA, Wallace GR, Stanford MR. Intercellular adhesion molecule-1 gene polymorphisms in Behcet's disease. Eur J Immunogenet 2000;27:73-76.

597. Annunen S, Paassilta P, Lohiniva J, Perala M, Pihlajamaa T, Karppinen J, Tervonen O, Kroger H, Lahde S, Vanharanta H, Ryhanen L, Goring HH, Ott J, Prockop DJ, Ala-Kokko L. An allele of COL9A2 associated with intervertebral disc disease. Science 1999;285:409-412.

598. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-1376.

599. Donn RP, Davies EJ, Holt PL, Thomson W, Ollier W. Increased frequency of TAP2B in early onset pauciarticular juvenile chronic arthritis. Ann Rheum Dis 1994;53:261-264.

600. Sanjeevi CB, Miller EN, Dabadghao P, Rumba I, Shtauvere A, Denisova A, Clayton D, Blackwell JM. Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:1397-1404.

601. Meulenbelt I, Bijkerk C, De Wildt SC, Miedema HS, Breedveld FC, Pols HA, Hofman A, Van Duijn CM, Slagboom PE. Haplotype analysis of three polymorphisms of the COL2A1 gene and associations with generalised radiological osteoarthritis. Ann Hum Genet 1999;63:393-400.

602. Keen RW, Hart DJ, Lanchbury JS, Spector TD. Association of early osteoarthritis of the knee with a Taq I polymorphism of the vitamin D receptor gene. Arthritis Rheum 1997;40:1444-1449.

603. Fife MS, Fisher SA, John S, Worthington J, Shah CJ, Ollier WE, Panayi GS, Lewis CM, Lanchbury JS. Multipoint linkage analysis of a candidate gene locus in rheumatoid arthritis demonstrates significant evidence of linkage and association with the corticotropin-releasing hormone genomic region. Arthritis Rheum 2000;43:1673-1678.

604. Baerwald CG, Mok CC, Tickly M, Lau CS, Wordsworth BP, Ollier B, Panayi GS, Lanchbury JS. Corticotropin releasing hormone (CRH) promoter polymorphisms in various ethnic groups of patients with rheumatoid arthritis. Z Rheumatol 2000;59:29-34.

605. Takagi H, Ishiguro N, Iwata H, Kanamono T. Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J Rheumatol 2000;27:1638-1642.

606. Quadri SA, Taneja V, Mehra NK, Singal DP. HSP70-1 promoter region alleles and susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 1996;14:183-185.

607. Khani-Hanjani A, Lacaille D, Hoar D, Chalmers A, Horsman D, Anderson M, Balshaw R, Keown PA. Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet 2000;356:820-825.

40


608. Yang YS, Kim SJ, Kim JW, Koh EM. NRAMP1 gene polymorphisms in patients with rheumatoid arthritis in Koreans. J Korean Med Sci 2000;15:83-87.

609. Tuokko J, Pushnova E, Yli-Kerttula U, Toivanen A, Ilonen J. TAP2 alleles in inflammatory arthritis. Scand J Rheumatol 1998;27:225-229.

610. Funkhouser SW, Concannon P, Charmley P, Vredevoe DL, Hood L. Differences in T cell receptor restriction fragment length polymorphisms in patients with rheumatoid arthritis. Arthritis Rheum 1992;35:465-471.

611. Morgan AW, Griffiths B, Ponchel F, Montague BM, Ali M, Gardner PP, Gooi HC, Situnayake RD, Markham AF, Emery P, Isaacs JD. Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. Arthritis Rheum 2000;43:2328-2334.

612. Nieto A, Caliz R, Pascual M, Mataran L, Garcia S, Martin J. Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis. Arthritis Rheum 2000;43:735-739.

613. Morinobu A, Kanagawa S, Koshiba M, Sugai S, Kumagai S. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjogren's syndrome in Japanese individuals. Arthritis Rheum 1999;42:2612-2615.

614. Tassiulas IO, Aksentijevich I, Salmon JE, Kim Y, Yarboro CH, Vaughan EM, Davis JC, Scott DL, Austin HA, Klippel JH, Balow JE, Gourley MF, Boumpas DT. Angiotensin I converting enzyme gene polymorphisms in systemic lupus erythematosus: decreased prevalence of DD genotype in African American patients. Clin Nephrol 1998;50:8-13.

615. Tsao BP, Cantor RM, Grossman JM, Shen N, Teophilov NT, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, Rotter JI. PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. J Clin Invest 1999;103:1135-1140.

616. Naves M, Hajeer AH, Teh LS, Davies EJ, Ordi-Ros J, Perez-Pemen P, Vilardel-Tarres M, Thomson W, Worthington J, Ollier WE. Complement C4B null allele status confers risk for systemic lupus erythematosus in a Spanish population. Eur J Immunogenet 1998;25:317-320.

617. Pullmann R Jr, Lukac J, Skerenova M, Rovensky J, Hybenova J, Melus V, Celec S, Pullmann R, Hyrdel R. Cytotoxic T lymphocyte antigen 4 (CTLA-4) dimorphism in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1999;17:725-729.

618. Sabbagh N, Marez D, Queyrel V, Lo Guidice JM, Spire C, Vanhille P, Jorgensen C, Hachulla E, Broly F. Genetic analysis of the cytochrome P450 CYP2D6 polymorphism in patients with systemic lupus erythematosus. Pharmacogenetics 1998;8:191-194.

619. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-1354.

620. Jarjour W, Reed AM, Gauthier J, Hunt S 3rd, Winfield JB. The 8.5-kb PstI allele of the stress protein gene, Hsp70-2: an independent risk factor for systemic lupus erythematosus in African Americans? Hum Immunol 1996;45:59-63.

621. Huang DF, Siminovitch KA, Liu XY, Olee T, Olsen NJ, Berry C, Carson DA, Chen PP. Population and family studies of three disease-related polymorphic genes in systemic lupus erythematosus. J Clin Invest 1995;95:1766-1772.

622. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus [published erratum appears in Tissue Antigens 1997 Dec;50(6):699]. Tissue Antigens 1997;49:635-639.

623. Sullivan KE, Wooten C, Goldman D, Petri M. Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:2046-2051.

41


624. Fugger L, Morling N, Ryder LP, Georgsen J, Jakobsen BK, Svejgaard A, Andersen V, Oxholm P, Karup Pedersen F, Friis J, et al. NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNF alpha) region in four autoimmune diseases. Tissue Antigens 1989;34:17-22.

625. Ozaki Y, Nomura S, Nagahama M, Yoshimura C, Kagawa H, Fukuhara S. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron 2000;85:86-91.

626. Huang D, Giscombe R, Zhou Y, Lefvert AK. Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. J Rheumatol 2000;27:397-401.

627. Gencik M, Meller S, Borgmann S, Fricke H. Proteinase 3 gene polymorphisms and Wegener's granulomatosis. Kidney Int 2000;58:2473-2477.

628. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993;85:1159-1164.

629. Daly AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR. Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. BMJ 1993;307:481-482.

630. Inatomi H, Katoh T, Kawamoto T, Matsumoto T. NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 1999;6:446-454.

631. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 1999;35:191-196.

632. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999;84:220-224.

633. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes. Jpn J Cancer Res 1992;83:866-870.

634. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA. FEBS Lett 1990;263:131-133.

635. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997;57:1194-1198.

636. Genest JJ, Jr., Ordovas JM, McNamara JR, Robbins AM, Meade T, Cohn SD, Salem DN, Wilson PW, Masharani U, Frossard PM, et al. DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease. Atherosclerosis 1990;82:7-17.

637. Saha N, Tong MC, Tay JS, Jeyaseelan K, Humphries SE. DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients. Clin Genet 1992;42:164-170.

638. Ichihara S, Yamada Y, Fujimura T, Nakashima N, Yokota M. Association of a polymorphism of the endothelial constitutive nitric oxide synthase gene with myocardial infarction in the Japanese population. Am J Cardiol 1998;81:83-86.

639. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.

42


640. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, Rossi F, Rizzoni D, Cusi D, Agabiti-Rosei E. Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 1997;15:1707-1710.

641. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension [published erratum appears in Lancet 1997 Aug 16;350(9076):524]. Lancet 1997;349:1353-1357.

642. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, Herwig J, Usadel KH, Badenhoop K. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab 1997;82:143-146.

643. Noda K, Matsutani A, Tanizawa Y, Neuman R, Kaneko T, Permutt MA, Kaku K. Polymorphic microsatellite repeat markers at the glucokinase gene locus are positively associated with NIDDM in Japanese. Diabetes 1993;42:1147-1152.

644. t Hart LM, Stolk RP, Heine RJ, Grobbee DE, van der Does FE, Maassen JA. Association of the insulin-receptor variant Met-985 with hyperglycemia and non-insulin-dependent diabetes mellitus in the Netherlands: a population-based study. Am J Hum Genet 1996;59:1119-1125.

645. Li SR, Baroni MG, Oelbaum RS, Stock J, Galton DJ. Association of genetic variant of the glucose transporter with non-insulin-dependent diabetes mellitus. Lancet 1988;2:368-370.

646. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.

647. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-1981.

648. Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999;104:158-163.

649. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997;49:56-61.

650. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett 1997;222:187-190.

651. Kehoe P, Williams J, Lovestone S, Wilcock G, Owen MJ. Presenilin-1 polymorphism and Alzheimer's disease. The UK Alzheimer's Disease Collaborative Group. Lancet 1996;347:1185.

652. Margaglione M, Seripa D, Gravina C, Grandone E, Vecchione G, Cappucci G, Merla G, Papa S, Postiglione A, Di Minno G, Fazio VM. Prevalence of apolipoprotein E alleles in healthy subjects and survivors of ischemic stroke: an Italian case-control study. Stroke 1998;29:399-403.

653. Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease. Neurosci Lett 1997;221:202-204.

654. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nothen MM, Kalow W, Kennedy JL. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998;19:123-132.

655. Lim LC, Powell JF, Murray R, Gill M. Monoamine oxidase A gene and bipolar affective disorder. Am J Hum Genet 1994;54:1122-1124.

43


656. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, Smith CA. Polymorphism in serotonin transporter gene associated with susceptibility. Lancet 1996;347:731-733.

657. Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Muller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP. A novel functional polymorphism within the promoter of the serotonin. Mol Psychiatry 1996;1:453-460.

658. Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, Gutman GA, Crocq MA, Ganguli R, Nimgaonkar V, Morris-Rosendahl DJ, Gargus JJ. Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate for schizophrenia and bipolar disorder?. Mol Psychiatry 1998;3:32-37.

659. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nothen MM. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996;97:614-619.

660. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, Takahata R, Koh J, Sakai J, Takai A, Inada Y, Asaba H. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996;67:103-105.

661. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T, Hopkin JM. Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet 1998;19:119-120.

662. Shirakawa T, Mao XQ, Sasaki S, Enomoto T, Kawai M, Morimoto K, Hopkin J. Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population. Hum Mol Genet 1996;5:1129-1130.

663. Danis VA, Millington M, Hyland V, Lawford R, Huang Q, Grennan D. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995;12:127-133.

44


Supplementary Table 1 (for website)

Number of diseases/traits associated with different genes

Gene # associated diseases/traits TNF 20ACE 14VDR 14MTHFR 13GSTM1 11APOE 10CTLA4 9CYP1A1 9GSTT1 9CYP2D6 7DIA4 7EPHX1 7GSTP1 7NAT2 7NOS3 7SLC6A4 7ADRB2 6COMT 6DRD2 6HTR2A 6LTA 6SERPINA8 6TP53 6APOB 5DRD3 5DRD4 5F2 5F5 5SLC11A1 5TGFB1 5ALDH2 4GNB3 4HRAS 4HTR6 4IL10 4IL1RN 4MBL2 4NAT1 4PLA2G7 4PPARG 4SERPINA3 4

45


SERPINE1 4SLC6A3 4SOD2 4AGTR1 3C4A 3CCK 3CCR2 3CCR5 3CDKN1A 3CYP17 3CYP1B1 3CYP2E 3ESR1 3F13A1 3FCGR2A 3GCK 3HTR5A 3ICAM1 3IFNG 3INS 3INSR 3NPPA 3PON1 3TAP1 3TAP2 3A2M 2ABCC8 2ADRB3 2APOA1 2AR 2BCL2 2BDKRB1 2CD4 2CETP 2CFTR 2COL1A1 2CYBA 2DRD5 2ENG 2ETS1 2FGB 2GNAS1 2GP1BA 2GYS1 2HSD11B2 2HSPA1A 2

46


HSPA2 2HSPA8 2HTR2C 2IL1B 2IL4 2IL6 2IRS1 2ITGA2 2ITGB3 2LHB 2LPL 2MAOA 2MAOB 2MC1R 2MMP3 2NOS1 2NOS2A 2PGR 2PLAT 2SERPINA1 2TF 2TPH 2XRCC3 2ACP1 1ADA 1ADD1 1ADH1B 1ADH4 1ADORA2A 1ADPRT 1ALAD 1ALOX5 1AMPD1 1APBB1 1APC 1APOA4 1APOC1 1APOC2 1APOD 1ATP1A3 1BCHE 1BCL3 1BLMH 1C4B 1CD14 1CD36 1

47


CD3D 1CDSN 1CHRNA4 1CMA1 1COL2A1 1COL9A2 1CRH 1CTSD 1CX3CR1 1CYP11A 1CYP11B2 1CYP19 1CYP2A6 1CYP2C19 1CYP2C9 1CYP3A4 1DBH 1DCP1 1DDC 1DLST 1DRD1 1EDNRA 1ELAC2 1EN2 1ERBB2 1ERCC1 1F3 1F7 1FCGR3A 1FGA 1FMR1 1FRDA 1FSHB 1FST 1GABRA5 1GABRB3 1GC 1GCGR 1GNAL 1GPX1 1GSTM3 1HFE 1HMBS 1HNMT 1HRH2 1HTR1B 1

48


IGHV2-5 1IGHV3-30-5 1IL13 1IL1A 1IL4R 1IL9R 1IMPA1 1IPF1 1KCNJ11 1KCNN3 1KLKB1 1LDLR 1LEP 1LIPE 1LRP1 1MAPT 1MGMT 1MLH1 1MMP1 1MMP9 1MPO 1MS4A1 1MSH3 1MSX1 1MTR 1MUC1 1MUC3A 1MYC 1MYCL1 1NEUROD1 1NMB 1NPY5R 1NTF3 1OPRM1 1OPRS1 1OTF3 1PCSK2 1PLA2G1B 1PLA2G4A 1PLCG1 1PON2 1PPP1R3 1PRNP 1PRTN3 1PSEN1 1PSMB8 1

49


PTPRC 1RARA 1REN 1RRAD 1SAH 1SCNN1B 1SCYA5 1SDF1 1SELE 1SELP 1SFTPA1 1SHBG 1SLC2A1 1SLC2A2 1SNAP25 1SNCA 1SRD5A2 1T 1TBXA2R 1TCF1 1TFCP2 1TGFA 1TGFB2 1TGFB3 1TH 1THBD 1THRB 1TNFRFS6 1TPMT 1TRA@ 1TRD@ 1TRHR 1UCHL1 1UCP3 1UGB 1UGT1A1 1VLDLR 1WFS1 1WRN 1XRCC1 1YWHAH 1

Gene symbols are as in Table 4. For each gene, the number of entries in Table 1 is shown.

50

Supplementary references (for...

Documents

Transcript of Supplementary references (for...